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ABSTRACT OF DISSERTATION

EPIGENETIC IMPLICATIONS IN INORGANIC ARSENIC-MEDIATED
CARCINOGENESIS
Chronic, low dose exposure to inorganic arsenic (iAs) is a public health concern
throughout the world, contributing to the development of many diseases, including lung
cancer. Several mechanisms for iAs-mediated carcinogenesis have been proposed, of
which the production of reactive oxygen species and formation of chromosomal
aberrations are the most studied. Another equally important, yet less studied mechanism
is dysregulation of epigenetic marks. “Epigenetics” refers to changes that occur on the
DNA and chromatin that do not alter base pair identity, but alter compaction, expression,
and regulation of specific DNA sequences. There are several types of epigenetic marks
including histone post-translational modifications, DNA methylation, and histone
variants. Understanding the role of these epigenetic regulators in iAs-mediated
carcinogenesis is, therefore, important because these aberrant changes influence the
disease phenotype. Specifically, these epigenetic changes have been implicated in a
process called the epithelial-to-mesenchymal transition, which allows cancer cells to
metastasize. First, this study used high-resolution microarray analysis to measure the
changes in DNA methylation in cells undergoing inorganic arsenic-induced epithelial-tomesenchymal transition, and on the reversal of this process, after removal of the
inorganic arsenic exposure. Inorganic arsenic exposure not only influences DNA
methylation, but we also identified for the first time that differential expression of
specific histone H2B variants occurs in iAs-exposed cells. The histone H2B variants,
which have point amino acid changes compared to the canonical sequence, exhibit
dysregulated expression patterns that are responding to iAs-induced changes in stem loop
binding protein (SLBP), which is responsible for regulating histone variant transcripts.
While the H2B variants have only a few small amino acid changes, some are located at
histone:DNA interfaces, while others are at histone:histone interfaces. These small amino
acid changes could cause steric and electrostatic changes which influence nucleosome
dynamics. Therefore, this study also sought to reveal how histone H2B variants influence
octamer and nucleosome stability. We found that histone H2B variants confer unique
stability and dynamic properties to both the histone octamer and the nucleosome.

Therefore, histone H2B variants are playing a unique role in chromatin dynamics, both in
iAs-induced carcinogenesis and normal chromatin functioning. In whole, this study
identified multiple epigenetic marks that are disrupted by iAs treatment and identified
how those epigenetic marks may be influencing chromatin compaction to promote the
epithelial-to-mesenchymal transition.
KEYWORDS: Inorganic Arsenic, DNA Methylation, Histone H2B Variants, Octamer
Stability, Nucleosome Stability, Stem Loop Binding Protein
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CHAPTER 1. BACKGROUND – EPIGENETIC REPROGRAMMING IN
INORGANIC ARSENIC-MEDIATED GENE EXPRESSION PATTERNS DURING
CARCINOGENESIS
Introduction
Inorganic arsenite (iAs) is a naturally-occurring toxic metalloid to which humans are
routinely exposed through the environment. It is widely distributed in the earth’s crust and
is ubiquitous in soil, water, and air. Humans are chronically exposed to iAs through
contaminated food and drinking water 1,2. It is estimated that contaminated wells, formed
from proximity to iAs-rich geological formations, expose 160 million individuals
worldwide to excessive levels of iAs1 (Figure 1.1). The long-term effects of low-dose iAs
exposure from contaminated drinking water continue as mining efforts, which release high
amounts of iAs into the groundwater, persist in many regions of the world1,3,4. While not
genotoxic, arsenic and iAs compounds are listed as known human carcinogens by the
National Toxicology Program2. Epidemiological studies demonstrate a strong relationship
between environmental iAs exposure and an increased cancer incidence. Such exposure
correlates with an increased risk of lymphatic 5, hematopoietic 6, skin, lung 5-7, digestive
tract 5, liver 6, urinary tract 6,8,9, and prostate 5,6 cancers. Although the precise mechanisms
by which iAs causes cancer remain elusive, several mechanisms have been proposed.
These mechanisms include iAs-induced oxidative stress, inhibition of DNA repair,
micronuclei formation, chromosomal aberrations, and changes to the epigenome. While
arsenic is present in the environment in several different forms, inorganic arsenite is known
to be the most toxic form. This is due to its high solubility in water (compared to organic
arsenic compounds) and lone electron pair that can participate in chemical bonds (more so
than arsenate which does not have an electron pair). This review will focus on proposed

epigenetic mechanisms that contribute to inorganic arsenic-induced toxicity and
carcinogenesis.

Proposed Mechanisms of iAs Mediated Carcinogenesis and Toxicity
A variety of mechanisms may contribute to the carcinogenicity caused by iAs. One
mechanism involves the iAs-induced production of reactive oxygen species (ROS). The
impact of iAs on ROS production is hypothesized to occur in two steps. First, iAs initiates
production of high ROS levels, which chemically react with DNA. This reaction damages
the DNA and disrupts its structural integrity, thus contributing to cellular transformation
and tumor proliferation

10,11

. Second, cells react to the increased amounts of ROS by

overexpressing the antioxidant enzymes superoxide dismutase, catalase, and glutathione,
which protect cells against apoptosis. The decreased apoptosis and accumulation of
damaged cells increases carcinogenic potential 10.
Chromosomal instability and epigenetic modifications may also play roles in the
carcinogenicity of iAs. At low doses, iAs does not cause DNA base pair mutations; instead,
it is known to generate double-stranded breaks 12, which result in large-scale chromosomal
aberrations

13

. This iAs-mediated chromosomal instability occurs frequently at

centromeres, leading to the formation of acentric chromosomes or the fusion of
centromeres between two chromosomes

14

. Fusion of two chromosomes at their

centromeres can cause improper chromosome segregation, which results in aneuploidy or
in micronuclei formation 12,15. On the other hand, fusion that occurs at chromosomal ends
may result in the formation of ring-like structures and/or participate in abnormal sister
chromatid exchanges 14,16; both of which are deleterious to the cell. While these are large12

scale chromosomal rearrangements, iAs also effects changes to chromatin structure at the
nucleosome level; these changes alter local chromatin conformation that ultimately finetune the iAs-mediated gene expression profile.
Eukaryotic DNA is packaged in the form of chromatin, which has a basic repeating
unit, the nucleosome. Each nucleosome consists of 147 DNA base pairs wrapped around
two molecules each of four canonical histones (histones H2A, H2B, H3, and H4). The tails
of these histones are subject to a variety of posttranslational modifications (PTMs)

17,18

,

which are dynamically regulated to control the accessibility of chromatin to factors that
direct gene expression. Histone PTMs, other epigenetic marks (e.g., methylated DNA or
distinctly-combined histone variants), and microRNAs are collectively known as
epigenetic regulators. The remainder of this review will focus on the most recent studies
that investigate the role of iAs exposure in reprogramming these epigenetic marks, and
how this reprogramming may mediate iAs toxicity.

DNA Methylation
DNA methylation (5mC) is one of several epigenetic mechanisms that cells use to
control gene expression. The effect of DNA methylation on a gene’s expression depends
on the type of regulatory element at which the methylation occurs. For instance,
methylation of a promoter is associated with gene repression. On the other hand,
methylation within the gene body is generally associated with gene expression and splice
regulation, although the latter processes are poorly understood.
The results of several studies have implicated aberrant DNA methylation in many
cancers but our understanding of the impact of iAs on DNA methylation is just emerging
13

19-21

. For instance, Zhao et al. showed that chronic, low-dose exposure of cells to iAs for

18 weeks caused global hypomethylation. Other studies revealed that iAs exposure to
human skin led to global hypomethylation of some tissues (leukocytes) and iAs exposure
in rodent liver instigated hypomethylation 22,23. However, other research indicates that iAs
exposure leads to hypermethylation at the promoters of specific tumor suppressor genes,
resulting in their repression

24,25

. For example, in iAs-exposed human hepatocytes,

significant hypermethylation of the promoters for genes involved in DNA repair such as
ERCC2 and RPA1, and of genes associated with the Wnt pathway like MYC and WNT2B,
were observed

24

. Additionally, significant hypermethylation of the promoters for the

tumor suppressor p16 26,27, and the DNA repair gene, MLH1 26, were observed in whole
blood obtained from humans chronically exposed to iAs. Conversely, iAs-induced
hypomethylation of promoters for genes involved in processes such as endocytosis and
RNA transport were also observed

24

. Interestingly, another study involving chronic

exposure of a human population to arsenic demonstrated hypomethylation at the promoter
of the DNA repair gene, ERCC2 28.
While these findings may at first seem incongruous, it is now clear that, although
global hypomethylation occurs, modifications at specific genetic loci can also be either
hypo- or hypermethylated. Furthermore, it is possible that some of these disparities may
be explained by the use of different model systems, different stages of malignant
transformation, and different experimental conditions (e.g., the dose of iAs, the duration
of iAs exposure, and the presence or absence of other carcinogens). For instance, Pilser et
al suggested that folate can influence iAs-mediated DNA methylation profiles in
peripheral blood leukocytes taken from Bangladeshi adults

14

23

. Overall, though, these

studies suggest that iAs-mediated malignant transformations result from multiple changes
in DNA methylation patterns, and that these altered patterns can have positive or negative
effects on the expression of specific genes. One should be cautious when drawing general
conclusions about observed iAs-induced changes in DNA methylation patterns from any
one study. Most importantly, profiling of DNA methylation changes should be performed
together with analyses of the functional consequences of such changes in DNA
methylation.
Researchers have proposed several possible mechanisms for iAs-mediated changes
in DNA methylation. In humans, DNA methylation at cytosine residues is initiated by the
de novo DNA methyltransferase 3 (DNMT3A and B) and maintained by DNA
methyltransferase 1 (DNMT1) 29. Following low dose iAs exposure, the expression of the
DNMTs is reduced, which results in less methylation at target sites 30-32. Because DNMTs
also participate in DNA repair, inactivation and/or reduction in the expression levels of
DNA methyltransferases will also impede DNA repair efficiency

25,31,33,34

. Another

possible explanation for iAs-mediated alterations in DNA methylation involves the
depletion of methyl groups. When cells metabolize arsenic, the arsenic methyltransferase,
AS3MT, transfers a methyl group from S-adenosylmethionine (SAM) to the arsenite 24,
depleting the available methyl groups needed by the DNMTs for DNA methylation 31. This
competition for methyl groups affects DNA methylation supported by DNMTs, but also
the histone methyltransferases. As the name implies, these enzymes methylate histones
and, likewise, are important components of epigenetic regulation. Interestingly, there is
interplay between DNA methylation and histone modification; thus, an imbalance in one
epigenetic mark could also trigger other epigenetic changes at specific gene regulatory

15

regions. Finally, iAs-mediated changes to DNA methylation may also occur through
altered DNA demethylase activity. TET1 and TET2 are the DNA demethylase enzymes
responsible for oxidizing 5mC to 5-hydroxymethylcytosine (5hmC). Recent studies
revealed that chronic iAs treatment leads to an upregulation in TET expression due to
enhanced binding of the CTCF transcription factor at the TET promoter. This finding is
complemented by the finding that chronic iAs treatment leads to an increase in global
5hmC levels. It is likely that iAs-induced changes to DNA methylation patterns are
instigated through each of these mechanisms working in concert.

Histone Modifications
Post-translational modifications (PTMs) of the N-terminal tails of histone proteins
change the chromatin structurally and functionally, thereby altering gene expression.
Histone PTMs include methylation, acetylation, phosphorylation, glycosylation,
carbonylation,

ubiquitylation,

biotinylation,

sumoylation,

citrullination,

ADP-

ribosylation, N-formylation, crotonylation, propionylation, and butyrylation, as well as
proline and aspartic acid isomerization. The sum of all of these histone PTMs is known as
the histone code 35. Histone PTMs permit, increase or restrict access to chromatin by gene
regulatory factors. Among the many that have been identified, the most extensively studied
and best understood histone PTMs in the context of transcriptional competency are
phosphorylation, methylation, acetylation, and ubiquitination 36.
Several in vitro studies have demonstrated that iAs exposure can result in global
changes in histone PTMs. These changes include increases in H3K9me2, H3K4me3, and
H3S10, decreases in H2B ubiquitination, and either increases or decreases in H3K27me3
16

37-42

. In addition, following iAs exposure in humans, blood cells exhibited an overall

decrease in H3K9me3, and H3K9ac, with an increase in H3K9me2

37,38

. Interestingly,

these studies also showed that the iAs-induced changes in histone PTMs can be genderspecific. For instance, a decrease in H3K27ac and H3K18ac and increase in H3K4me3 and
H3K27me3 was observed in iAs-exposed females, while the inverse trend was observed
in iAs-exposed males 37.
The majority of PTMs that affect chromatin accessibility are modifications to histone
H3 (e.g. H3K4, H3K9, H3K27, and H3K36). Methylation of H3K4 is performed by a
series of type 2 lysine methyltransferases (KMT2)

43

and occurs in a stepwise manner;

methylation proceeds from the mono- to the di- and, finally, to the trimethylation state.
While these different H3K4me states can occur throughout a gene, they each exhibit a
higher presence in specific locations. H3K4me1 most often occurs at the 3’ end of genes,
H3K4me2 occurs within the gene body, and H3K4me3 often occurs at gene promoters 43.
Deposition of H3K4me3 at gene promoters and coding regions correlates with
transcriptional activation

40,44,45

. Exposure of cells to iAs results in a global decrease in

monomethylated H3K4, with a corresponding increase in H3K4’s di- and trimethylated
states 40. This shift in the global H3K4 methylation status occurs quickly; exposing cells
to 1 μM sodium arsenite led to changes in H3K4 methylation states in as little as 24 hours
40

. Furthermore, Tyler et al found perinatal arsenic exposure resulted in changes to

H3K9Ac and H3K4me3 levels in the brains of adult mice 46,47.
Analogous to H3K4 methylation, H3K9 is first monomethylated and then
dimethylated by KMT1C (also known as G9a) euchromatic histone methyltransferase. The
dimethylated state is further converted to the tri-methylated state by KMT1A (also known
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as SUV39h1) 39,48. These methylation events are offset by KDM3A, a histone demethylase
that reverses the mono- or di-methylation of H3K9 39. Like methylated H3K4, the di- and
trimethylated states of H3K9 are typically found in different chromatin locations;
H3K9me2 tends to localize at the edges of the nucleus, where heterochromatin is more
common, while H3K9me3 is found in the center of the nucleus, where euchromatin
predominates 39,40. Exposure of A549 lung carcinoma cells to iAs increased expression of
KMT1C, leading to an increase in H3K9me2 and H3K9me3 levels

39

. Furthermore,

Chervona et al. observed a variety of correlations between iAs exposure and this type of
modification in peripheral blood mononuclear cells using a population-based study in
Bangladesh. This study further revealed a positive correlation between urinary iAs and
H3K9me2 37,49.
H3K27 methylation is another important PTM for histone H3. This repressive PTM
is mediated by the Polycomb Repressive Complex 2 (PRC2); PRC2 is composed of three
core components: Enhancer of Zeste 1 or 2 (EZH1/2), Suppressor of Zeste 12, (SUZ12),
and Embryonic Ectodermal Development (EED). The methylation state conferred by
PRC2 is determined by the homologue of EZH present in the complex—EZH1 mediates
the monomethylation of H3K27, while EZH2 mediates its di- and trimethylation.
H3K27me3 is associated with inactive promoters and gene silencing and, importantly, it
marks chromatin for further compaction by protein regulator of cytokinesis (PRC1) via
ubiquitylation of H2AK119 50. iAs exposure greatly increases the expression of the EZH2
homolog and of other PRC2 core components, resulting in a global increase in H3K27me3
levels 41. A persistent increase in EZH2 and the subsequent incorporation of H3K27me3
into chromatin silences the promoters of target genes, which is enhanced by the crosstalk
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that occurs between epigenetic marks. A clear example of this cross-talk is seen by the
reduced expressions of p19ARF and p16INK4a due to the incorporation of H3K27me3
and H3K9me2, and to the methylation of DNA at the INK4/ARF regulatory locus in iAsexposed cells 27,51,52.
It is well known that many changes in histone marks are mediated by histone kinases.
The kinase-mediated phosphorylation of histone H3 is one example that is associated with
cell proliferation and transformation 53,54. With regard to arsenic exposure, it is likely that
iAs activates a cell signaling pathway that modifies histones. For example, iAs induces the
activation of the nuclear mitogen and stress-activated protein kinase 1 (MSK1) via the p38
MAPK pathway

19,55

, and this process was necessary for iAs-induced transformation 56.

Interestingly, in response to stress, MSK1 phosphorylates KDM3A (p-KDM3A) at
Ser264, resulting in the enrichment and recruitment of STAT-1 and p-KDM3A to target
gene promoters. These events promote the localized demethylation of H3K9 with
consequential increased transcriptional activity
phosphorylate H3S10

58,59

57

. Additionally, MSK1 can directly

, which recruits scaffolding proteins to the promoters of

immediate early genes, including those of proto-oncogenes FOS and JUN, to induce their
activation 60.
Only a few studies have demonstrated a connection between histone phosphorylation
and arsenic-induced carcinogenicity. Studies have suggested that arsenic-induced H3
phosphorylation might be responsible for the up-regulation of the oncogenes c-fos and cjun 55. Most recently, Ray et al reported that iAs induces a coordinated regulation of Nrf2
and histone H3S10 phosphorylation, which activates the human heme oxygenase-1 gene

19

42

. These results reinforce the notion that iAs modulates gene expression by operating

through the JNK and p38/Mpk2 kinase pathway to promote cancer.
iAs may also modulate histone PTMs by activating the epidermal growth factor
(EGF) pathway

61

. Upon activation of this pathway, PKM2—a histone kinase—

translocates to the nucleus, where it binds and phosphorylates Thr11 on histone H3
(H3T11). This phosphorylation not only accelerates the demethylation of H3K9me3 by
the trimethylation-specific H3 methylase KDM4C, but also leads to the dissociation of
HDAC3, allowing the acetylation of H3 with subsequent transcription of oncogenes MYC
and CCND1

62

. By influencing this pathway, iAs may indirectly control the

phosphorylation and acetylation state of histones and therefore the expression patterns of
target genes.

Histone Variants
In addition to the four canonical histones, there are also highly conserved amino acid
sequence variants of these histones. The variants differ by only a few amino acids, and
their expression is generally lower than that of the canonical histones. Each histone variant
has a specific gene expression, and a distinct chromatin localization/incorporation that
confers, within the chromatin structure, information contributing to the cell-type, the stage
of differentiation and tissue. However, compared to the canonical histones, studies on
histone variants are limited, and so the role these chromatin-incorporated histone variants
play in normal cells and even in diseased states is only beginning to emerge. Our
understanding of the impact these histone variants have on chromatin biology is hindered
by a lack of high-resolution and sensitive assays to differentiate these proteins, as they
20

have very similar amino acid compositions to canonical histones. However, using highresolution Top-down mass spectrometry, recent studies from our laboratory showed that
some histone variants were dynamically altered during iAs-mediated malignant
transformation. Specifically, we showed that histone H2B variants were abnormally
expressed following iAs exposure, and during subsequent iAs-mediated epithelialmesenchymal transition (EMT) 63.We identified a total of 16 H2B variants, 13 somatic and
3 testis-specific; of the somatic variants, seven were upregulated while three were
downregulated

63-67

. The most significant changes observed in our study were the

upregulation of histones H2B1K and H2B1C, and downregulation of histones H2B1D and
H2B1B. The results demonstrated that although histones are highly conserved, changes in
single amino acids may influence chromatin dynamics that lead to transcriptional reprogramming critical for cell-type specificity and differentiation 67. Interestingly, removal
of iAs returned expression levels for some variants to normal levels while others remained
abnormal, suggesting that some epigenetic changes are transient 63. This iAs removal, and
its associated reversed gene expression, correlated with a reversal in the variant histones
expressed during EMT. Therefore, it is possible that the carcinogenic potential seen in
these cells is driven by expression patterns of histone variants that did not revert following
iAs removal.
iAs is known to disrupt the balance between canonical histone H3.1 and variant
histone H3.3. Histone H3.1 transcription levels are highest during S phase while H3.3
expression levels are consistently low throughout the cell cycle 68-73. Functionally, histone
H3.1 is ubiquitously present in genomic chromatin while histone H3.3 is incorporated into
DNA promoter regions to specifically facilitate transcriptional activation
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74,75

. iAs

treatment increases histone H3.1 stability and genomic incorporation, hindering the
interaction of histone H3.3 with chromatin and changed nucleosome composition; these
effects likely change the gene expression patterns

76

. Specifically, the irregular

incorporation of H3.1 could silence tumor suppressor genes and abnormally activate cell
cycle genes. The proposed mechanism for this iAs-mediated increased influence by H3.1
involves an associated inhibition of stem-loop binding protein (SLBP) expression

77,78

.

Under normal conditions, SLBP binds to the stem loop on histone transcripts and increases
their lifetime within the cell. With iAs exposure, SLBP levels are reduced due to reduced
transcription of the gene and more proteasomal degradation of the protein 70,76. With less
SLBP present, canonical histone transcripts with the stem loop are degraded, leaving those
with a polyadenylated tail (H3.1) intact. Indeed, addition of a poly(A) tail to histone
transcripts increases their stability so they may be present in higher levels outside of S
phase. This processing ultimately increases H3.1 levels, leading to more nucleosomal
incorporation, and blocks potential histone H3.3 interactions at strategic sites, causing
aberrant gene expression

76

. Knockdown of SLBP caused increased cell growth and

transformation, indicating that this mechanism may be implicated in arsenic-induced
carcinogenesis 76.
Other histone variants are implicated in carcinogenesis. For example, abnormal
expression of histone H2A.X, a histone variant involved in double stranded break repair,
genome stability, and tumor suppression 79-83 has been associated with progression of EMT
in colon and lung cancer

84,85

. When histone H2A.X levels are reduced, the variant is

depleted from the gene loci for Slug and ZEB1 (EMT markers) creating a relaxed
chromatin structure and increased expression 84. Upregulation of histone H2A.Z, another
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histone H2A variant, is implicated in colorectal and breast cancer

86-90

. Histone H2A.Z

contributes to the maintenance of the stability and integrity of the genetic material within
the cell 91,92. When this variant is upregulated, cell growth and proliferation increase by an
activation of cell cycle regulators and EMT markers such as E-cadherin and fibronectin
84,86,93

. Yet another set of histone H2A isoforms, H2A.1 and H2A.2, are repressive and

reduce tumorigenesis

94

. These histone variants typically act as tumor suppressors by

hindering the efficiency of transcription factor binding and chromatin remodeling at
strategic sites

95-98

. Finally, upregulation of CENP-A, a centromere-specific H3-like

histone, is thought to increase the incidence of aneuploidy and dysregulation of cell cycleassociated genes, and also is implicated in cancer

99

. Further research is needed to

determine if iAs-induced carcinogenesis and toxicity employ any of these cancer-related
histone variants.

MicroRNAs
MicroRNAs (miRNAs) contribute to another epigenetic mechanism of gene
regulation affecting development, growth, and the response to stress. Several in vitro and
human studies demonstrated arsenic-induced alterations in miRNA gene expression. For
instance, Marsit et al, showed global increases in miRNA expression in response to iAs
exposure

100

. In addition, miR-222 and miR-21 expressions were increased in the

peripheral blood of steel factory workers exposed to heavy metal particulate

101

. In

contrast, a study of Hong Kong children aged 12–19 years, found decreased expression of
both miR-21 and miR-221 associated with increased urinary arsenic and lead levels

102

.

Furthermore, in a pregnancy cohort from Mexico, maternal total urinary iAs was
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associated with the increased expression of 12 miRNAs in infant cord blood. This study
utilized genome-wide miRNA analysis, and suggests that miRNA alterations can lead to
gene expression changes in progeny

103

. Using transcriptome-wide next generation

sequencing, Yu and colleagues, identified expression changes for 36 new miRNAs from
iAs-tainted rice

104

. Another study in plants showed that iAs altered the expression of

miR167, miR319, and miR854 105. Investigations have pursued the function and potential
mechanism of these microRNA in iAs toxicity. For example, upregulation of microRNA21 can enhance the transformation potential of a cell by targeting PDCD4

106

. Another

functional mechanism identified is the iAs-mediated transformation in p53(low) HBECs,
which can be reversed by homeobox factor 1 (ZEB1 and ZEB2)-mediated increases in the
levels microRNA 200b107. Also identified, iAs-mediated autophagy is supported by
microRNA-21-induced PTEN-ERK signaling, and iAs-induced angiogenesis occurs
through a microRNA425-5p-regulated CCM3

108

. With the help of new technology,

additional iAs-associated miRNAs functions and processes will be discovered, revealing
the regulatory network that mediates iAs toxicity and carcinogenesis.

Alternative Splicing
Epigenetic regulation of gene expression occurs at the level of transcriptional
activation, as discussed above, but also through the less investigated process of splicing.
Alternative splicing (AS) of pre-mRNA occurs in many multi-exon genes and greatly
increases the diversity of the proteome. Aberrant splicing is known to occur in human
cancers 109-111, and a proposed mechanism is the substitutions of isoforms associated with
carcinogenesis 112, angiogenesis 113 and EMT 114,115. Epigenetic modifications are thought
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to regulate AS by two non-mutually exclusive means: 1) by affecting the kinetics of
polymerase elongation and 2) through recruitment of splicing regulatory factors. Two
types of epigenetic marks, DNA methylation 116-119 and histone PTMs 111,120-123, have been
implicated in the selection of exon-candidates. Exposure to iAs significantly alters DNA
methylation 124 and histone PTMs 38-40,52,125-127, and so it is reasonable to expect that this
exposure can induce changes in alternative splicing. Indeed, we recently showed that lowdose iAs exposure results in changes in AS 124, though the mechanism remains unknown.
One possible mechanism by which iAs influences AS may be through an inhibition
of DNA binding by alternative splicing regulators such as CCCTC-binding factor (CTCF)
and poly (ADP) ribose polymerase (PARP1) 123,128,129,. Interestingly, PARP1 co-localizes
with CTCF on chromatin; this complex, with CTCF-dependent automodification of
PARP1, permits PARylation activity in the absence of DNA damage 128,130. Importantly,
many splicing factors are regulated by PARylation 131-135 and any iAs-mediated inhibition
of PARP1 binding to DNA not only affects the structural properties of chromatin but also
the PARylation activities, which indirectly affect splicing decisions. In addition, the
binding of proteins to DNA can be altered by the presence of iAs due to the high binding
affinity of this metalloid for cysteine residues that are found in C4 and C3H1 zinc finger
motif-containing proteins such as PARP1

136-138

. Other DNA-binding proteins with zinc

finger motifs inhibited by iAs are the methylcytosine dioxygenases (TET1/2), needed to
oxidize 5-methylcytosine to 5-hydroxymethylcytosine and 5-carboxylcytosine

139

.

Inactivation of TET1/2 by iAs allows 5-methylcytosine to accumulate at CTCF target sites
and prevents CTCF from binding to its target sites, resulting in exon exclusion

25

117

. In

summary, if iAs blocks the binding of PARP1 or CTCF to DNA, the chromatin-associated
functioning of these proteins is altered, which includes splicing decisions.
A second possible mechanism by which iAs may alter AS is by increasing the
presence of p52 through activation of the non-canonical NF-κB pathway

140

. P52 co-

localizes and interacts with the splicing factor SRSF1 to modulate splicing 120. The role of
SRSF1 in carcinogenesis is well studied 141, and its expression is upregulated by MYC 142,
which in itself is deregulated in iAs exposure

24,143

. MYC also directly upregulates core

pre-mRNA machinery during carcinogenesis and maintains appropriate splicing of
alternative exons 144.
The dominant isoform expressed for any given gene is tissue specific and may result
from differentially expressed splicing regulatory factors among tissue types 145-147. Since
changes in AS are likely to vary from tissue to tissue, dissecting and understanding the
complicated issue of what drives iAs-mediated carcinogenesis is complex task.

Conclusion
A large body of research has implicated low dose arsenic exposure in
carcinogenesis and EMT. This review examines the impact of epigenetic processes,
including DNA methylation, histone PTMs, histone variants, and alternative splicing, on
carcinogenesis mediated through iAs exposure. While all of these epigenetic marks are
associated with iAs-induced carcinogenesis, additional research is required to clarify the
mechanism(s) driving each system. Expanded research in this area will delineate the role
of iAs exposure in the initiation and development of cancer.
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Figure 1.1 Estimated population with arsenic greater than 10 micrograms per liter.

Map showing estimated population in each county in the United States that is exposed to
arsenic via groundwater above 10 µg/L. (Figure from United States Geological Survey)
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CHAPTER 2. MATERIALS AND METHODS
HeLa Cell Growth and Arsenic Treatment
HeLa cells were grown using Dulbecco’s modified Eagle medium (DMEM; SigmaAldrich) supplemented with 10% fetal bovine serum (Sigma-Aldrich), 1% MEM
nonessential amino acids (Sigma-Aldrich), and 1% penicillin-streptomycin (SigmaAldrich). Cells were grown in a humidified chamber at 37°C and 5% CO2 until they
reached 80% confluency. For iAs exposure (iAsT cells), cells were treated with 0.5 µM
sodium arsenite (Sigma-Aldrich) for approximately 45 days. Time matched controls were
treated with water (nontreated or NT cells). Reverse-treated cells (RT cells) were treated
with 0.5 µM sodium arsenite until day 36, at which point they were treated with water
instead of sodium arsenite. Reverse-treated cells were harvested 10 days after treatment
reversal (day 46).

BEAS-2B Cell Growth and Arsenic Treatment
BEAS-2B cells were grown using DMEM (Sigma-Aldrich) supplemented with 10%
fetal bovine serum (Sigma-Aldrich), 1% MEM nonessential amino acids (Sigma-Aldrich),
and 1% penicillin-streptomycin (Sigma-Aldrich). Cells were grown in a humidified
chamber at 37°C and 5% CO2 until they reached 80% confluency. For W3, W8, and W17
treatment groups, cells were treated with 0.5 µM sodium arsenite (Sigma-Aldrich) for
three, eight, and seventeen weeks, respectively. Cells in the 2.0T treatment group were
grown with 0.5 µM sodium arsenite for 20 weeks, and then grown in 2 µM sodium arsenite
for six weeks. Time matched controls were treated with water (nontreated or NT cells).
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Reverse-treated cells (RT) were treated with 0.5 µM sodium arsenite for 20 weeks, then
treated with 2 µM sodium arsenite for six weeks. This was followed by three weeks of
growth without sodium arsenite treatment. Reverse-treated cells were harvested 3 weeks
after treatment reversal.

Quantification of the 5-Methylcytosine Level in DNA
Genomic DNA was isolated from the cells and total 5-methylcytosine (5-mC) was
determined using the 5-mC DNA ELISA kit (Zymo Research Corp.) according to the
manufacturer’s instruction. Briefly, DNA is denatured and then treated with an anti-5methylcytosine monoclonal antibody that is both sensitive and specific for 5-mC. A
secondary antibody containing horseradish peroxidase is then used to detect 5mC. Values
are expressed as a percent 5-mC in a DNA sample calculated through a standard curve
generated with specially designed controls that are included in the kit. Each ELISA was
performed in triplicate and students t-test performed to determine statistical significance.

Infinium MethylationEPIC Bead Chip – Methylation array analysis
Sample preparation for the Chip. Genomic DNA from nontreated, treated, and
reverse treated cells was extracted using the Qiagen DNeasy Blood and Tissue kit; samples
were initially bisulfite converted using the Zymo EZ-96DNA Methylation Kit (Catalog
#D5004) Deep-Well Format. DNA was treated with sodium bisulfite causing
unmethylated cytosines to convert to uracil while keeping methylated cytosines
unchanged. Then, 4µl (equivalent to 750ng DNA) of the bisulfite-converted DNA was
used as input for the Illumina Infinium HD Methylation Array. During this process, the
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bisulfite converted DNA samples were denatured, neutralized, and prepared for
amplification. The amplified DNA was enzymatically fragmented and precipitated. The
resuspended

DNA

samples

were

then

dispensed

onto

Illumina's

Infinium

MethylationEPIC BeadChip148, where they underwent a series of washing, extension, and
staining procedures. The BeadChips are then coated for protection and scanned on the
Illumina HiScanHQ. Once scanning was completed, the data were uploaded into
GenomeStudio for preliminary and quality control analysis.
Data analyses. Target success rates were determined and the detection p-value was
calculated as 1-p from the background model characterizing the chance that the target
sequence was distinguishable from the negative control148. Poor performing targets were
defined as having p>0.05 and were discarded. Sample replicates were checked for an r2
value greater than 0.99. For statistical analysis, beta values were calculated. The
methylation levels of CpGs were described as beta values (0 to 1) representing the
calculated level of methylation (0% to 100%). We had two technical and two biological
replicates processed by chip technique. The Pearson correlation coefficients (PCCs) were
>0.99 for all the replicates, confirming a good level of reproducibility for the chip process
and indicating that the observed differential methylation between the cells (treatments)
represented true biological differences. Functional normalization was performed using
home scripts ‘Minfi preprocessFunNorm’ which does the background normalization.
Additionally, the dye correction was performed using noob149. All CpG sites with a
detection value > 0.05, CpG sites with SNPs, as well as probes predicted to hybridize to
more than one genomic location (identified by McCartney et al. in Genomics Data, 2016)
were removed.
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Isolation of Total RNA and Production of cDNA
RNA was isolated from 1x107 cells using the RNeasy Plus Mini Kit (Qiagen). RNA
was eluted in 0.5X TE. One microgram of RNA was used in a reverse transcriptase reaction
with iScript Reverse Transcriptase (Bio-Rad) to prepare cDNA and cDNA was diluted
1:10 in water.
Recipes
0.5X TE: 5 mM Tris, 0.5 mM EDTA pH 8.0

Isolation of PolyA RNA and Production of cDNA
For extraction of polyadenylated RNA, total RNA was extracted from approximately
ten 1x107 cell pellets and combined to collect 10 µg of total RNA for each BEAS-2B
treatment group. Polyadenylated mRNA was isolated from approximately 10 µg of total
RNA using the PolyATtract mRNA Isolation System (Promega). One microgram of polyA
mRNA was used in a reverse transcriptase reaction with poly(dT) primers with the
Superscript IV First-Strand Synthesis System (Thermo Fisher Scientific) to prepare cDNA
and cDNA was diluted 1:20 in water.

Quantitative Real Time PCR
Each quantitative real-time PCR (qRT-PCR) reaction contained 25 ng of cDNA and
followed a variation of the following reaction protocol: 1) 94°C for 5 min; 2) 94°C for 30
sec; 3) 50-65°C for 30 sec; 4) 72°C for 45 sec; 5) repeat 2-4 for 40 cycles; 6) 72°C for 10
min. Reactions were run and data was collected on Bio-Rad CFX96 Real Time System.
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Primers are listed in supplementary table. qRT-PCR data was analyzed by the 2-ddCt method
and student t-tests were performed to determine statistical significance.

Histone Extraction
1x107 BEAS-2B cells were resuspended in 1 ml of TEB and incubated with shaking
at 4°C for 10 minutes, then centrifuged at 3000 RPM for 10 minutes at 4°C. The pellet was
then washed again in TEB and centrifuged. The remaining pellet was incubated in 0.2N
HCl and incubated with shaking overnight at 4°C. The lysate was then centrifuged for 10
minutes at 4°C and the supernatant was dialyzed against two changes of 0.1N acetic acid
for 2 hours each. This was followed by dialysis against three changes of water, with the
last dialysis going overnight. Histones were removed from the dialysis tubing and
concentrated using Amicon Millipore Ultra-10 centrifugal filter units. Histone extract
purity was determined using Western Blot analysis.
Recipes
TEB: 2 mM PMSF, 0.01% NaN3, 0.005% TritonX100, in Dulbecco’s phosphate buffered
saline

Western Blot
For whole cell protein extraction, 5x106 HeLa or BEAS-2B cells were homogenized
in 1X RIPA buffer and then intermittently sonicated with 12 cycles of 30s bursts/30s rest
(Diagenode Biodisruptor 300). Cell lysate was then centrifuged at 13000 rpm at 4°C for
15 minutes to pellet cell debris. For nuclear protein extraction, 1x107 HeLa or BEAS-2B
cells were resuspended in a hypotonic solution and kept on ice for 15 minutes. Then, NP32

40 was added to the cellular lysates to a final concentration of 0.5% and the lysates were
centrifuged at 3000 RPM for 10 minutes 4°C to remove cellular debris, leaving only the
nuclei. The nuclei were then resuspended in 1X RIPA and kept on ice for 30 minutes. This
was followed by centrifugation at 13,000 RPM for 30 minutes at 4°C to remove nuclear
debris. Whole cell and nuclear protein concentration was measured using a BCA kit
(Thermo Fischer Scientific) and 50-100 µg of total protein were run on a 15% SDS-PAGE
gel at 120 V until loading dye (GoldBio) reached the bottom of the gel. Proteins were
electrotransferred to polyvinylidene fluoride membranes (PVDF) at 65 V for 90 min on
ice. 5% milk + phosphate buffered saline with Tween (PBST) was used to block nonspecific binding to the membranes. Membranes were incubated with primary antibodies
(in 0.5% nonfat powdered dry milk + PBST) overnight at 4°C and then with secondary
antibody (α-Rabbit or α-Mouse) the next day. Proteins were visualized with ECF (GETyphoon FLA9500) as outlined by the manufacturer.
Recipes
1X RIPA: 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 25 mM
Tris-HCl pH 7.4
Hypotonic Solution: 20 mM Tris-HCl pH 7.4, 10 mM NaCl, 3 mM MgCl2
15% SDS-PAGE Separating Gel: 15% Acryl/Bis 29:1, 0.375 M Tris pH 8.8, 0.1% SDS,
0.1% APS, 1X TEMED
4% SDS-PAGE Stacking Gel: 4% Acryl/Bis 29:1, 0.125 M Tris pH 6.8, 0.1% SDS, 0.1%
APS, 1X TEMED
1X PBST: 0.0002% Tween in phosphate buffered saline
Blocking Buffer: 5% dry milk powder, 1X PBST
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Actinomycin Treatment
To analyze decay rate of histone H2B transcripts, 1x106 BEAS-2B cells for each
treatment group were plated in each well of a 6-well plate with 2 ml of liquid media.
Actinomycin D (Sigma) was added to each well to a final concentration of 5 ug/ml.
Treatment was stopped at 0 hours, 30 min, 60 min, and 4 hours by adding trypsin and
pelleting cells by centrifugation at 3000 RPM for 3 minutes. qRT-PCR was performed for
several histone H2B variant transcripts to detect mRNA levels. Decay was determined
using 0 time point as control.150

Salt Fractionation of Chromatin
Salt fractionation begins with chromatin extraction and digestion. For chromatin
extraction, 5x106 BEAS-2B cells from each treatment group were lysed in TM2 buffer
containing a final concentration of 0.5% NP40 for 5 minutes on ice with gentle vortexing.
Cellular debris was removed by centrifugation at 2000 RPM for 5 minutes at 4°C. This
was followed by a 10 minute wash in TM2 buffer and another centrifugation. For
chromatin digestion, the appropriate concentration of micrococcal nuclease (MNase,
Thermo Fisher Scientific) and length of digestion must be experimentally determined. In
my experiments, chromatin was MNase digested at an MNase concentration of 5 U/ml for
15 minutes at 37°C. Digestion was stopped with the addition of EGTA to a final
concentration of 8 mM. A portion of the sample was removed and saved as the “Nuc”
fraction. Then, the remaining sample was centrifuged at 2000 RPM for 10 minutes at 4°C
to remove cellular debris and a portion of the supernatant was removed and saved as the
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“Sup” fraction. The remaining pellet was incubated in a Triton buffer containing 80 mM
salt for 2 hours at 4°C with rotation. After this incubation, chromatin was pelleted by
centrifugation at 2000 RPM for 10 minutes at 4°C and the supernatant was collected as the
“80 mM” fraction. This incubation with Triton buffer containing salt was repeated with
increasing concentrations of NaCl (150 mM, and 600 mM NaCl) for 2 hours. After each
incubation, the sample was centrifuged and supernatant was taken. After all three
incubations with Triton buffer, the final pellet was resuspended in TNE buffer. To detect
DNA content, 50 µl of each fraction was incubated with 2 mg/ml Proteinase K for 1 hour
at 37°C and then purified with PCR Cleanup (Qiagen). DNA was eluted in 0.5X TE and
run on an agarose gel. To detect protein content, 15 µl of each fraction was loaded onto an
SDS-PAGE gel. For both DNA and protein gels, band size and density were measured and
compared.
Recipes
TM2 Buffer: 10 mM Tris-HCl pH 7.4, 2 mM MgCl2, 0.5 mM PMSF
TNE Buffer: 10 mM Tris-HCl pH 7.4, 200 mM NaCl, 1 mM EDTA
80 mM Triton Buffer: 70 mM NaCl, 10 mM Tris-HCl pH 7.4, 2 mM MgCl2, 2 mM EGTA,
0.1% Triton X-100, 0.5 mM PMSF
150 mM Triton Buffer: 140 mM NaCl, 10 mM Tris-HCl pH 7.4, 2 mM MgCl2, 2 mM EGTA,
0.1% Triton X-100, 0.5 mM PMSF
600 mM Triton Buffer: 585 mM NaCl, 10 mM Tris-HCl pH 7.4, 2 mM MgCl2, 2 mM EGTA,
0.1% Triton X-100, 0.5 mM PMSF
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Nucleosome Reconstitution
Mononucleosomes were reconstituted using double dialysis of free 147 bp 601
DNA151 and histone octamer, with DNA present in molar excess (1:25 to histone octamer).
Dialysis occurred with two changes against “no salt” reconstitution buffer, one for six
hours and one overnight. After dialysis, the contents of the dialysis button were extracted
and nucleosomes were separated from free DNA using a sucrose gradient. The sucrose
gradient was made (as described below) and the contents of the dialysis button were gently
loaded on top. The sucrose gradient was centrifuged for 22 hours at 41,000K at 4°C using
a Ti-41 rotor. After centrifugation, the sucrose gradient was fractionated by hand into 400
µl fractions. The fractions were kept on ice and fractions 8-27 were run on a 5% TBE
native gel for 1.5 hr at 300 V. Native gels were stained in 1X GelStar™ Nucleic Acid Gel
Stain (Lonza) in 1X TBE for 30 minutes and imaged on a Typhoon FLA 9500 (GE
Healthcare) using the ECF filter. Fractions containing nucleosome and no contaminating
DNA were combined, concentrated, and buffer exchanged into 0.5X TE using Millipore
Amicon Ultra-15 centrifugal filter units.
Recipes
Reconstitution Buffer with 2M NaCl: 0.5X TE, 1 mM benzamidine hydrochloride, 2M NaCl
Reconstitution Buffer without NaCl: 0.5X TE, 1 mM benzamidine hydrochloride

Sucrose Gradient
Sucrose gradients were made using the BioComp model 108 gradient master™
according to manufacturer protocol. An SW-41Ti tube containing 30% sucrose in the
bottom portion and 5% sucrose in the top portion was rotated on the Gradient Master
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Platform for 1 minute and 36 seconds at an 81.5° angle at speed 19. Sucrose gradients must
be made fresh using chilled sucrose solutions and used immediately to prevent diffusion
and loss of gradient. The sucrose solutions were stored at 4°C.
Recipes
5% Sucrose: 5% sucrose in 0.5X TE (W;V)
30% Sucrose: 30% sucrose in 0.5X TE (W:V)

Thermal Stability Assay
For each reaction, a master mix of reagents and either octamers or nucleosomes
was created and pipetted into individual wells of a 96 well plate. Then, SYPRO Orange
(Thermo Fisher Scientific) was added to a final concentration of 5X. Each reaction was
run on the Bio-Rad CFX Real-Time Detection System with a protocol that increased the
temperature by one degree each minute from 20-90°C. For each run, replicates were
averaged and normalized and the melting temperature, at which point the slope was the
steepest on the melting curve, was determined.
Recipes
Reaction Mixture with Octamer: 2.25 µM histone octamer, 5X SYPRO Orange, 20 mM
Tris-HCl pH 7.5, 1 mM DTT, 2M NaCl
Reaction Mixture with Nucleosome: 0.5 µM histone octamer, 5X SYPRO Orange, 20 mM
Tris-HCl pH 7.5, 1 mM DTT, 2M NaCl
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MNase Digestion
601 DNA containing 50 bp linker DNA on either end was created containing P32 αATP. DNA was run on 14% TBE native gel and band containing DNA was cut out. DNA
was incubated in Crush-N-Soak Buffer overnight and ethanol precipitated. Radiolabeled
DNA was then concentrated and buffer exchanged into 0.5X TE 20 mM NaCl.
Nucleosomes were reconstituted according to protocol above. 50 ng of nucleosomes were
incubated with 10 U/µl MNase for increasing amounts of time and stopped using stop
solutions. Then, digested DNA was purified from reaction mixtures using Qiagen PCR
Cleanup Kit. DNA was eluted in 30 µl 0.5X TE, mixed with Orange G (Sigma Aldrich),
and run on 5% TBE gel for 1.5 hours. Gels were placed on screen overnight and imaged
using Typhoon.
Recipes
Crush-N-Soak Buffer: 0.75 M ammonium acetate, 0.3 M sodium acetate, 1 mM EDTA pH
8.0, 0.1% SDS
Reaction Mixture: 50 ng nucleosome, 1.5 mM CaCl2 100 ug/ml BSA, 5% glycerol, 25 mM
NaCl, 1 mM DTT, 10 mM Tris pH 7.4, 10 U/ml MNase
Stop Solution 1: 0.25 M EDTA, 0.1 M EDTA
Stop Solution 2: 10 mg/ml, 0.1% SDS, 0.02 M EDTA
5% TBE Gel: 5% Acryl/Bis 29:1, 10% ethylene glycol, 1X TBE, 0.1% SDS, 1X TEMED
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CHAPTER 3. TRANSIENT AND PERMANENT CHANGES IN DNA
METHYLATION PATTERNS IN INORGANIC ARSENIC-MEDIATED
EPITHELIAL-TO-MESENCHYMAL TRANSITION
Introduction
Environmental inorganic arsenic (iAs) exposure through contaminated water
consumption represents a major public health concern
cardiovascular diseases

6,152

, diabetes

156

1,152-155

and has been linked to

, and a variety of cancers including lung

157

,

colorectal 158, kidney 157, liver 22,157 and skin cancers 159,160. Inorganic arsenic is not a direct
mutagen, rather it acts through other mechanisms to induce cellular transformation and
epithelial-to-mesenchymal transition (EMT)

13,161

. Several mechanisms have been

proposed to describe how iAs-induced toxicity promotes carcinogenesis; these include the
induction of oxidative stress

162-164

, inhibition of DNA repair, and chromosomal

aberrations 13,165. In addition to these mechanisms, recent findings indicate that epigenetic
factors, such as DNA methylation, play a central role in aberrant gene expression resulting
from iAs exposure 39,136,166,167.
DNA methylation, the most stable epigenetic mark, is a key factor in regulating gene
expression

168,169

. This mark is added to DNA by DNA methyltransferases (DNMTs);

DNMT1 is responsible for the maintenance methylation while DNMT3a and DNMT3b
perform de novo methylation

170,171

. DNA methyltransferases facilitate this modification

by the transfer of a methyl group from S-adenosyl methionine (SAM) to the 5’ carbon of
cytosine residues 170. This modification normally occurs in regions/contexts of high CpG
density, known as CpG islands (CGIs). However, DNA methylation can also occur in nonCGI contexts. CGIs are typically concentrated at promoter regions but can be found in
other regions

172

and methylation controls gene expression differently depending on its
39

location. The presence of 5-methylcytosine at promoters is usually associated with
transcriptional repression

172

. Conversely, absence of this mark, along with the presence

of the appropriate transcription factors, promotes gene expression. However, within gene
bodies and at intergenic regions, the effects of methylation are less definitive; therefore,
studies are in process to elucidate the dynamic effects of DNA methylation in those
contexts. Since methylation can affect transcription factor binding ability 173, it is possible
that DNA methylation functions prominently in cell and tissue identity and functionality.
Several mechanisms have been proposed to describe how iAs affects the DNA
methylation profile in cells. The first involves the metabolism of inorganic arsenic. During
iAs metabolism, arsenic methyltransferase (AS3MT) transfers a methyl group to arsenite,
using SAM as a donor 24; this process could lead to a depletion of SAM, which is needed
for a variety of other cellular processes and the sole donor for DNA methylation. A second
mechanism involves changes in the expression of DNMTs in response to chronic exposure
to iAs. In trying to understand why DNMTs would be targeted, we found that the
transcriptional repressor CTCF is targeted by iAs treatment, causing changes in CTCF
occupancy at DNMT promoters

174-176

. Such disruption in the DNMT expression would

effect changes in DNA methylation patterns.
Several studies that focus on profiling of the global changes in DNA methylation
levels have been carried out in cells exposed to iAs; however, these studies have used lowresolution genome profiling techniques to investigate methylation patterns

177

. Clearly

missing is an analysis of DNA methylation patterns at gene regulatory regions such as
CpG islands, promoters, and enhancers. Recently, we carried out the first comprehensive
study of DNA methylation changes with single-nucleotide resolution for cells chronically
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exposed to low doses of arsenic

174

. In the present study, we extend our findings to

determine changes in iAs-induced DNA methylation patterns in cells with chronic lowdose iAs exposure, as well as in cells that undergo a reversal of this treatment. Our studies
include the analysis of DNA methylation profiles and correlations of gene expression
changes in the cells, combining unbiased whole-genome and candidate gene approaches.
In this study, we aim to determine the effect of iAs on both permanent and reversible
changes in DNA methylation and gene expression that drive EMT. Our lab previously
showed that removal of iAs resulted in a reversal of some gene expression patterns 63,124.
We reasoned that since epigenetic marks are reversible, some methylation patterns would
revert to the nontreated condition when iAs is removed, thereby reversing some gene
expression patterns, while others would remain stable. We therefore investigated the
adaptive changes after reversal of the exposure.

Results
3.2.1 Cellular Transformation and EMT
To determine the effect of iAs on the epithelial-to-mesenchymal transition (EMT),
we used the common cervical cancer cell line, HeLa, which has been used extensively to
study cell signaling and EMT 124,178,179. Interestingly, though carcinogenic, HeLa cells can
still undergo EMT 180, and specifically, iAs-induced EMT 63,124. In our experimental design
(Figure 3.1A), HeLa media was replenished with 0.5 µM sodium arsenite every three to
four days for 45 days to allow cells to undergo iAs-mediated EMT (iAsT). This low-dose
treatment simulates chronically exposed, environmentally relevant iAs levels that many
people in mining regions experience 1,2,181. We confirm our previous results showing that
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chronic low-dose treatment of cells with iAs resulted in epithelial-to-mesenchymal
transition in HeLa cells 63,124,174. In addition, after continuous exposure, iAs was removed
from some cultures and those cells were grown in media without iAs for 10 more days.
We called this period of treatment without iAs “inorganic arsenic exposure reversal” (iAsrev) and its purpose is to simulate situations where people are removed from chronic iAs
exposure (Figure 3.1A).
In previous studies, we observed EMT through cell morphology as well as through
qRT-PCR and western blot analyses of EMT markers

63,124,174

. Morphologically, we

observed that NT cells maintained an epithelial phenotype in which cells were round and
small. Upon iAs treatment, cells developed a more mesenchymal phenotype, being
elongated and spindle-shaped, suggestive of EMT

63,124

. Through qRT-PCR and western

blot analyses, we observed changes to cellular markers characteristic of cells undergoing
the EMT process. Cell adhesion markers, such as β-catenin, Claudin-1, Claudin-3, and
ZO-1, are expected to decrease in expression while transcription factors that promote a
mesenchymal phenotype, such as Snail, Slug, and Vimentin, are expected to increase in
expression

63,124

. Additionally, upon reversal of treatment, we found that some EMT

markers exhibited a moderate reversal in expression and protein levels (β-catenin, Slug,
and Snail) while others did not revert (Claudin-3 and Vimentin) 63. To validate that EMT
is occurring in our current studies, we analyzed protein expression changes for EMT
markers using western blot analysis and the changes in protein levels indicate that the cells
indeed had undergone EMT (Figure 3.1B). We found that Claudin-1 decreased in protein
levels upon treatment and that Slug, N-cadherin, and Snail increased upon treatment. After
reversal of treatment, some markers exhibited a moderate reversal such as Slug and N-
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cadherin, indicating that there was some reversal of the EMT conditions albeit not
completely. Conversely, Claudin-1 and Snail did not revert back toward non-treated levels,
which we also saw in previous studies (Figure 3.1B). These results corroborate our
previous data, indicating that cells treated with low doses of inorganic arsenic undergo
EMT and that this transition is partially reversed when inorganic arsenic is removed.

3.2.2 Global DNA methylation level
After demonstrating that HeLa cells undergo EMT in response to iAs treatment and
partial reversal with iAs withdrawal, we next identified the DNA methylation changes
present in iAsT and iAs-rev cells. We first determined the levels of global DNA
methylation in these samples using the Zymo 5-mC DNA ELISA assay. We found
significantly higher DNA methylation levels in iAsT cells compared to NT cells (Figure
3.2). In line with our reversal of EMT markers, we observed a reduction in global DNA
methylation levels in iAs-rev cells compared to iAsT cells, and the amount of DNA
methylation more closely resembled those in NT cells (Figure 3.2). We interpret these data
as indicating that global DNA methylation is reprogrammed in these cells and may
correlate with changes in gene expression patterns.

3.2.3 Quantification of DNA methylation at specific sites
Since the 5mC DNA ELISA assay is a low-resolution technique that measures DNA
methylation levels, the Infinium MethylationEPIC BeadChip Array was used to further
interrogate the differential methylation patterns globally, and at specific genes targeted in
iAs-mediated EMT and reversal. This array has 853,307 CpG (850K) sites, providing the
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ability to interrogate DNA methylation changes not only at promoters and gene bodies,
but also at unexplored regions such as enhancers148. Indeed, incorporated into this Chip
are 333,265 CpG sites, including enhancer regions identified by the ENCODE 182,183 and
FANTOM5

184

projects. Thus, this is a valuable tool to decipher how DNA methylation

changes in unexplored territories, such as enhancer sequences, contribute to arsenicmediated diseases.

3.2.4 Global Methylation Changes
To identify possible targets for iAs-mediated DNA methylation reprogramming, we
conducted methylation profiling of the NT, iAsT, and iAs-rev cells. We filtered DNA
methylation data according to the following criteria: methylation changes should be more
than two-fold and should have a p-value < 0.05 (Supplemental Figures 3.1 and 3.2). Of the
853,307 CpG sites, significant differences in DNA methylation were observed at 30,530
unique CpG sites in iAsT when compared to NT, of which 67% (20,314 CpG) were
hypermethylated and 33% (10,216 CpGs) were hypomethylated (Figure 3.3). Upon
reversal of arsenic treatment, some of the methylated sites did not revert to normal
methylation in NT conditions. A total of 53% of the DMRs still differed from NT cells;
77% of these CpGs (10,996 CpGs) were hypermethylated, while 23% (3,3339 CpGs) were
hypomethylated (Figure 3.3). We then compared the DMRs in iAsT cells and iAs-rev cells.
We observed that ~40,000 sites had reverted towards the wildtype status - 20,997
hypomethylated and 20,589 hypermethylated (Figure 3.3). We hypothesize that although
many DMRs revert to NT conditions, some were not reversed completely and so were still
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measured as DMRs by our analysis. While these global measurements are useful, they do
not show differential methylation at specific gene regulatory regions.

3.2.5 iAs-mediated DNA methylation changes in CGIs and non-island regions
Methylation is often concentrated at CGIs but can also be found in the regions
surrounding CGIs (Figure 3.4A). According to Illumina, a CGI is defined as a region in
which there is GC content greater than 50% in at least a 200 base pair region148.
Comparative analysis of the methylation patterns in CGIs, shores, shelves and open seas
revealed significant differences in methylation patterns across NT, iAsT, and iAs-rev cells
in certain CGI-related regions. The shelves (2000-4000 bp from CpG island, in blue),
across all of the comparisons, only exhibited 2-3% hypo- or hypermethylation changes,
indicating that DNA methylation of these specific regions may not play a prominent role
in iAs-mediated EMT (Figure 3.4B-D, all pie charts). For the shores (less than 2000 bp
from CpG island, in purple), a slight decrease in hypomethylation was observed when
comparing iAs-rev v. NT and iAsT v. NT (Figure 3.4B and C, top pie charts). The most
prominent changes in hypomethylation were observed within the CGIs (in orange) and
open sea regions (over 4000 bp from CpG island, in green). There was an increase in
hypomethylation (15% to 25%) at CGIs upon reversal (Figure 3.4B and C, top pie charts).
On the other hand, in the open sea regions, the amount of hypomethylation was reduced
upon reversal (55% to 49%) (Figure 3.4B and C, top pie charts). This shift in the ratio of
CGI to open sea hypomethylation could suggest that hypomethylation changes at the CGIs
are more permanent while hypomethylation changes at the open seas are more transient
and more prone to reversal when iAs treatment is removed.
45

In the shores (in purple), a slight increase in hypermethylation was observed when
comparing iAs-rev v. NT and iAsT v. NT, which compensates for the slight decrease in
hypomethylation, noted above (Figure 3.4B and C, bottom pie charts). This shift in
differential methylation at the shores was confirmed by the presence of more
hypermethylation than hypomethylation in the iAs-rev v. iAsT comparison in Figure 3.4D.
This finding could suggest that the changes in the hypomethylated loci are more transient,
or that the hypermethylation previously observed in treated cells is more permanent. At
the CGIs, there is an increase in hypermethylation (11% to 14%) upon arsenic withdrawal,
similar to the increase in hypomethylation in that region (Figure 3.4B and C, bottom pie
charts). For iAs-rev v. iAsT, the CpG islands exhibited 12% hypomethylation and 13%
hypermethylation (Figure 3.4D). In the open sea regions, the amount of hypermethylation
was reduced from 66% to 61% upon reversal (Figure 3.4B and C, bottom pie charts). Both
hypo- and hypermethylation were reduced to a similar extent in the open seas after arsenic
treatment was removed. When comparing iAs-rev to iAsT, the open sea represented 64%
of the hypomethylated regions and 58% of the hypermethylated regions (Figure 3.4D).
The decrease in hypermethylation at the open seas and the increase in hypermethylation at
CGIs after iAs withdrawal (which was also seen with hypomethylation) could indicate that
differential methylation in the open seas is not as permanent as differential methylation in
the CGIs.

3.2.6 iAs-mediated DNA methylation changes in Genes and Gene Regulatory Regions
There are several regulatory regions within a gene that modulate gene expression and
repression (Figure 3.5A). We asked if there were any transient and/or permanent iAs46

mediated methylation changes within these regions. We compared the methylation profiles
across different regions of genes – 5’ and 3’ UTRs (orange and gray respectively), gene
body (purple), first exon (green), and regions 200 and 1500 base pairs (bp) upstream to the
transcription start sites (TSS200 blue and TSS1500 red). When compared to NT cells,
differential hypomethylation in iAsT cells is as follows – 25% at TSS1500, 11% at
TSS200, 15% at 5’UTR, 6% at first exon, 41% within the gene bodies and 2 % within the
3’UTR (Figure 3.5B, left bar). In all regions analyzed, there is a similar amount of hypoand hypermethylation changes, except at the gene body and TSS1500, where we observed
41% hypomethylation to 49% hypermethylation and 25% hypomethylation to 19%
hypermethylation. (Figure 3.5B). We next asked if these methylation changes can be
reversed by comparing DNA methylation patterns in NT cells and iAs-rev cells. Focusing
mainly on the regions that were strongly differentially methylated, we first observed a 30%
hypomethylation and a 45% hypermethylation change within the gene body (Figure 3.5C).
This seems to indicate a reversal of methylation patterns when considering the changes
seen in iAsT cells in the gene body region. Surprisingly, we also observed a dramatic
change in methylation at the first exon – 22% hypomethylation and 6% hypermethylation
(Figure 3.5C). However, our understanding of the implication of this shift in
hypomethylation towards the first exon at the moment is not clear. Furthermore, the
TSS1500, which exhibited 25% hypomethylation and 19% hypermethylation in iAsT cells
compared to NT cells (Figure 3.5B), also exhibited differential methylation in the reverse
treated cells (Figure 3.5C). In reversed conditions, compared to NT cells, the differential
methylation pattern is 18% hypomethylation and 20% hypermethylation, which is the
opposite of what was observed in iAsT cells, indicating that reversal of methylation
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patterns may be occurring upon removal of iAs treatment. In most cases, we observed
some reversal in DNA methylation though it was not complete. To test directly if this is
true, we compared methylation patterns in iAsT v. iAs-rev cells. Here too, we still
observed differential methylation at the sites tested. The gene body had 52%
hypomethylation and 48% hypermethylation (Figure 3.5D). The TSS1500 exhibited 20%
hypomethylation and 24% hypermethylation (Figure 3.5D). These findings verify that
reversal of iAs treatment reversed DNA methylation patterns in gene regulatory regions,
albeit not completely.
In order to better understand the DNA methylation changes occurring in genic
regions, we performed Venn diagram comparisons of the differentially methylated genes.
To begin, we compared those genes that are differentially methylated after iAs treatment
(iAsT v. NT) with those that are differentially methylated after reversal of treatment (iAsrev v. NT). The overlapping genes, of which there are 3582, are genes that had more
permanent changes in methylation (Supplemental Figure 3.3A); our reasoning being that
these differential methylation patterns are present in both iAsT and iAs-rev cells.
Next, we identified those genes whose methylation patterns reversed after removal
of iAs by comparing genes that were differentially methylated after treatment (iAsT v. NT)
to those that are differentially methylated between iAs-rev and iAsT cells. This comparison
resulted in 6825 overlapping genes (Supplemental Figure 3.3B). We consider these genes
as those with methylation patterns that had reversed to normal conditions because the iAs
methylation state is similar to NT but different from iAsT cells. This is further confirmed
by looking at the overlap of genes that were hypomethylated in the iAs-T cells and those
that were hypermethylated in the iAs-rev. Comparing these groups showed that about 82%
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of hypomethylated genes in iAsT showed hypermethylation in the iAs-rev (3472 genes of
4236 total genes), while 71% of genes that were hypermethylated in iAsT showed
hypomethylation in iAs-rev cells (4103 genes of 5774 total genes) (Supplemental Figure
3.4).
Finally, we compared genes that were differentially methylated in iAs-rev cells to
those that were differentially methylated between iAs-rev and iAsT cells. There were 4490
overlapping genes and we interpret these genes as those that are in transition between the
NT and iAsT methylation state since their methylation state did not remain permanently
changed but also did not completely revert to normal levels (Supplemental Figure 3.3C).

3.2.7 iAs-mediated DNA methylation changes at promoter associated regions
Promoter methylation is normally associated with gene repression. Thus, to gain
insight into the function of iAs-mediated reprogramming of DNA methylation patterns,
we next focused our analyses of DNA methylation changes at promoter regions.
Comparing iAsT to NT cells, we observed a near 50% hypomethylation in promoterassociated regions, of which 3.71% hypomethylation was associated with cell type specific
promoter regions (Figure 3.6A, top pie chart). This result is reasonable considering we are
using the same cell type throughout this study. We next investigated if hypomethylation
changes in promoter associated regions persisted after reversal of treatment. It seems that
in iAs-rev cells (iAs-rev v. NT), there was little change – 48.58 % to 49.03%, in promoterassociated hypomethylation in iAsT cells compared to iAs-rev cells (Figure 3.6A and B,
top pie charts). This may suggest that hypomethylation in promoter associated regions is
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stable and permanent and does not revert back to normal conditions upon reversal of iAs
treatment.
We next analyzed hypermethylation at promoters. In iAsT cells, there was 38%
hypermethylation in promoter-associated regions with 3.24% hypermethylation associated
with cell type specific promoter regions when compared to NT cells (Figure 3.6A, bottom
pie chart). Interestingly, after withdrawal of iAs treatment (iAs-rev v. NT), there was a
large increase in hypermethylation at promoter-associated regions (38.16% to 60.66%)
(Figure 3.6A and B, bottom pie charts). This was also accompanied by a decrease in
hypermethylation in unclassified regions (25.68% to 19.8%) and unclassified cell type
specific regions (30.83% to 14.78) (Figure 3.6A and B, bottom pie charts). This shift in
ratio could suggest that hypermethylation in promoter-associated regions is more
permanent while hypermethylation in unclassified regions is more transient and able to
revert back to normal levels after iAs withdrawal. The stark increase in hypermethylation
at promoter-associated regions is validated by a higher ratio of hypermethylation than
hypomethylation in that region in the iAs-rev v. iAsT comparison (Figure 3.6C). While
investigating DNA methylation changes within specific gene regions is advantageous for
understanding their function, our understanding of DNA methylation in non-promoter
regions is still in its infancy. In this study, we have focused our attention to promoter and
gene body methylation at specific genes and the correlation of their methylation status to
gene expression levels.
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3.2.8 Coupling of differential methylation and differential gene expression at specific
loci
Next, we asked whether these differential methylation patterns affect gene
expression at the transcript level. DNA methylation at the promoters of genes is typically
associated with gene repression, and demethylation correlates with increased gene
expression

172,173

. On the other hand, the function of DNA methylation within gene body

regions is not as definitive. It seems that methylation in the gene body functions in a
manner opposite to that in the promoter region

185,186

. In gene bodies, hypomethylation

correlates with gene repression while hypermethylation correlates with gene expression
186

. Additionally, DNA methylation in the gene body has been linked to regulation of

alternative splicing so the full breadth of its function is still poorly understood 116,118,187.
To examine the impact of DNA methylation changes on gene expression in our
experimental conditions, RNA was extracted from NT, iAsT and iAs-rev cells. This RNA
was converted to cDNA and used for quantitative real time PCR analysis (qRT-PCR). For
this analysis, we chose genes that showed significant differential methylation (Figure 3.3)
at the promoter region or within the gene body and that could potentially be implicated in
EMT.
The first gene examined was CORO1B, which is important in cell motility regulation
188

, and has hypomethylation at the promoter region (Table 3.1). qRT-PCR analysis at the

transcript level of this gene showed an increase in gene expression in iAsT cells (Figure
3.7A), correlating with the observed hypomethylation at the promoter region of this gene
(Table 3.1). The level of gene expression remained high even after iAs was removed (iAsrev cells), indicating that this change is more permanent. Interestingly, we were not able
to identify any significant change in DNA methylation at the promoter of this gene in iAs51

rev cells, possibly due to the cutoff stringency applied in the differential methylation
analysis. The second gene we tested was PPME1, which plays a role in malignant glioma
progression

189

. qRT-PCR analysis showed no increase in gene expression in iAsT cells,

though our genome-wide methylation data indicated this region as being hypermethylated
(Table 3.1). This could possibly be explained by the fact that not all CpGs regulate gene
expression. On the other hand, in iAs-rev cells, a significant increase in gene expression
was observed (Figure 3.7A), We also investigated the PPM1L gene, which is known to
repress apoptosis 190. Expression levels of this gene were increased in both iAsT and iAsrev cells compared to NT cells (Figure 3.7A). These gene expression changes correlated
positively with the increase in DNA methylation in the gene body of this gene in both iAsT
and iAs-rev cells compared to NT cells (Table 3.1).
Five genes exhibited prominent downregulation after iAs treatment (Figure 3.7B).
For CDH12, expression decreased in iAsT cells and this decrease persisted with iAsreversal (Figure 3.7B). CDH12 is a type II classical cadherin protein 191 and the changes
in its expression correlated with gene body hypomethylation, as well as promoter
hypermethylation, in iAsT cells compared to NT cells (Figure 3.7B and Table 3.1). The
decrease in expression from iAsT to iAs-rev also correlates with promoter
hypermethylation identified in our genome-wide methylation studies. ARID5B, which is
involved in histone demethylase complexes 192, had a decrease in expression in iAsT cells
and remained at that level even in iAs-rev cells (Figure 3.7B). This is somewhat surprising
considering ARID5B has hypomethylation in its promoter region in iAs-rev cells (Table
3.1). For DYNC1I2, a member of the dynein intermediate chain family 193, a decrease in
gene expression was observed in iAsT cells compared to NT cells, while iAs removal
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resulted in upregulation of DYNC1I2 (Figure 3.7B), correlating with the promoter
hypomethylation observed in the microarray (Table 3.1). PRDX1, a peroxiredoxin family
member, showed a decrease in expression during iAs treatment correlating with promoter
hypermethylation in iAsT cells (Figure 3.7B and Table 3.1). After removal of iAs, gene
expression returned to normal levels (Figure 3.7B). Lastly, gene expression at the EPC1
gene, a polycomb group member

194

, correlated to the observed methylation changes –

decreased gene expression in iAsT cells compared to NT cells with moderate reversal in
iAs-rev cells, corresponding with gene body hypomethylation in iAs-rev compared to NT
cells. So too, an increase in gene expression in iAs-rev cells compared to iAsT cells
corresponded to the observed hypermethylation at the gene body of the EPC1 gene for
iAs-rev v. iAsT (Figure 3.7B).
The fact that expression of some genes such as PPM1L, DYNC1I2, PRDX1, and
EPC1 reverted to normal levels in iAs-rev and that those gene expression changes correlate
to reversal of DNA methylation patterns suggests the role of epigenetics in this process.
However, other changes instigated by iAs treatment were more permanent, such as the
gene expression changes seen for CORO1B, PPME1, CDH12, and ARID5B and suggest
that either these epigenetic factors were not reversed within the time frame allowed or that
other factors together with epigenetics are stabilizing a more permanently changed gene
expression state of the gene.

3.2.9 Global correlation of gene expression patterns with DNA methylation patterns
In order to further understand the biological significance of differential methylation
in iAsT and iAs-rev cells, we examined the overlap of genes that were both differentially
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methylated as well as differentially expressed at the transcript level. For this analysis we
reanalyzed our previous dataset (GSE60760) of iAs-mediated differentially expressed
genes 124. To understand the pathways targeted in iAsT, we analyzed the overlap between
genes differentially expressed in iAsT cells and those differentially methylated in iAsT
cells. There were 270 genes that were both differentially methylated and differentially
expressed in cells treated with inorganic arsenic (Supplemental Figure 3.5A). For the sake
of simplicity, Venn diagram analysis was performed on all genes that were differentially
expressed as well as differentially methylated.
We then performed gene ontology (GO) analyses using the Gene Set Enrichment
Analysis (GSEA) to identify regulatory pathways affected by both differential methylation
and differential expression. Our analyses show that signal transduction pathways and
development processes are enriched, indicating that these pathways are targeted by iAs
(Table 3.2). Since we observed that iAsT cells were undergoing EMT, we analyzed the
target genes for oncogenic signatures. Our analysis showed that some of the genes with
differential methylation and differential gene expression are involved in abnormal
expression of K-RAS (an oncogene) in epithelial cells, particularly lung, breast, and kidney
tissue (Supplemental Table 3.1).
We next asked if these pathways are still targeted in iAs-rev cells. We identified 187
genes that are both differentially methylated and differentially expressed in iAs-rev cells
(Supplemental Figure 3.5B). These genes represent those whose methylation patterns did
not revert to normal levels and therefore appeared to be permanently changed. GO analysis
of these genes showed enrichment in biological processes such as development and
metabolic processes (Table 3.3). Investigating the oncogenic signature of these genes also
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revealed that they are involved in abnormal expression of K-RAS in lung, breast, and
kidney epithelial tissue, similarly to iAsT cells (Supplemental Table 3.2). This could
indicate that while some genes are reverting back to normal levels of expression, the genes
that do not revert are driving the carcinogenic potential of iAs treatment.
Finally, we investigated those genes that are differentially methylated between iAsrev cells and iAsT cells. These genes represent the group of genes that are transient and
return to a more normalized condition after iAs removal (Supplemental Figure 3.5C). GO
analysis of these genes revealed enrichment in biological processes such as signal
transduction, metabolism, and cell death (Table 3.4). Their oncogenic signatures again
showed dysregulation of K-RAS in epithelial cells in lung, kidney, and breast tissue
(Supplemental Table 3.3). A complete gene ontology listing of these genes with regards to
their hyper- and hypomethylation state is found in Supplemental Tables 3.4-3.6.
In summary, we show that differential methylation correlates with differential
expression, both during treatment and after the reversal of treatment. While some
differential methylation and differential expression changes remained after reversal of
treatment, others reversed back to normal conditions. Since the breadth of the impact of
methylation is not completely known, we also observed that some methylation patterns
which were reversed did not correlate with changes in gene expression. Additionally, it
seems that even though some genes are reversed, the cells are still poised in an oncogenic
state, as revealed by the oncogenic signatures. However, our data provides a platform
enabling the probing of DNA methylation patterns, reversal of those patterns, and the
function either in promoting direct gene expression and/or in the possible recruitment of
factors that might aid in gene expression. This is especially intriguing as we observed that
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the K-RAS regulatory process might be specifically targeted by iAs in disease
pathogenesis.

Discussion
To date, few studies have identified specific gene loci that are differentially
methylated in response to chronic iAs exposure. The dose used in our experiments is
biologically relevant and mimics the dosage many living in mining regions are exposed to
daily

1,2,181

. Sadly, in some countries, people are exposed to even higher amounts on a

regular basis

156,177,195

. Ours is the first study to distinguish between permanent and

reversible DNA methylation changes using data from cells with treatment reversal. The
treatment group that experienced reversal of treatment is also biologically relevant as it
imitates the case in which people move away from an area that has chronic low dose
arsenic exposure, quit smoking, or otherwise remove themselves from environments where
they are experiencing high levels of inorganic arsenic. All of these situations happen
frequently and while these people experience a cessation of exposure, the biologic effects
may still persist, as shown by this study.
Our studies show that chronic low-dose exposure to iAs leads to global methylation
changes (Figures 3.2 and 3.3) as well as differential methylation in gene regulatory regions
(Figures 3.4-3.6) and specific genes (Table 3.1). Differential methylation is concentrated
to CGIs (Figure 3.4), upstream promoter regions, and gene bodies (Figure 3.5). The
differential methylation correlates to changes in gene expression which may be a driving
factor in the epithelial-to-mesenchymal transition (Figure 3.1 and 3.7). Upon reversal of
treatment, some methylation and expression changes revert to normal conditions and
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others do not (Figure 3.7 and Table 3.1). Ontology analysis of genes targeted in iAsmediated differential methylation patterns revealed an enrichment of cellular processes,
such as cell signaling and development, after initial iAs exposure and enrichment of
processes involved in metabolism after iAs withdrawal (Tables 3.2-3.4).
Our study is unique in its investigation of biological consequences of removal of iAs
exposure. The initial insult of chronic low dose exposure to iAs is clearly detrimental due
to its ability to cause cellular transformation and EMT 63,124,174. However, the ramifications
of iAs exposure do not fully disappear when exposure ends. It appears that while some
changes partially revert back to normal conditions after exposure is removed, many
changes remain in their abnormal state (Figure 3.1). Previous studies showed this partial
reversal in morphology, gene expression and protein levels of EMT markers, DNA
methylation patterns, and gene expression patterns 63,124,174. What we are showing now is
methylation and gene expression changes due to withdrawal of iAs exposure. For DNA
methylation and its effect on gene expression, we hypothesize that the genes that remain
differentially methylated and expressed, such as CORO1B and CDH12, are driving
transformation and EMT, while those that revert back to normal levels of methylation and
expression, such as DYNC1I2 and EPC1, are involved in early adaptation to iAs exposure
and are less involved in transformation and EMT. Additional studies will be needed to
identify specific genes as drivers or passengers. By identifying specific genes that are
differentially methylated between iAsT and its withdrawal, we can parse out which genes
are still altered after reversal and which revert to a more normal phenotype. We
hypothesize that as cells undergo iAs-mediated EMT, hypomethylation may be occurring
at oncogenes while hypermethylation may be occurring at tumor suppressors.
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We are also intrigued and encouraged by the fact that our previous studies in BEAS2B cells and our current study in HeLa cells show similar results in EMT markers, DNA
methylation patterns, and carcinogenic potential 63,124,174. This finding indicates that HeLa
cells can be used as an effective model for chronic low-dose iAs-mediated epithelial-tomesenchymal transition. We witnessed similar changes in cell morphology expression and
protein levels of EMT markers in both cell types. Additionally, we found that DNA
methylation correlates to changes in gene expression patterns that contribute to EMT for
both cell types. Furthermore, HeLa cells and BEAS-2B cells returned similar gene
ontology results for pathways and processes that are being targeted in iAs treatment such
as cell signaling and neurogenesis (Tables 3.2-3.4) 174. As would be expected, there were
some minor differences between the results we observed in HeLa cells compared to BEAS2B cells. For example, BEAS-2B cells had slight global hypomethylation while HeLa cells
had slight global hypermethylation upon treatment

174

. Differences could be due to the

state of the cells used in the experiments. In our earlier studies, we used non-carcinogenic
cells, whereas in this study, HeLa cells are already carcinogenic. Even though one cell line
is carcinogenic and the other is not, iAs caused EMT in both and we believe that similar
mechanisms are driving EMT in both cell lines. Transformation and carcinogenesis are
dynamic processes that rely on several mechanisms, EMT being one of them. It seems that
in HeLa cells, iAs treatment pushes EMT even further. It would be interesting to compare
the changes seen in BEAS-2B and HeLa to determine which changes are contributing to
cellular transformation and which are contributing to EMT.
For the most part, our expression data matched what we would expect based on the
methylation present in the gene (Figure 3.7). However, a few genes, such as PPME1,

58

exhibited expression changes that were opposite of what we would expect due to the
methylation data. One explanation is that not every CpG is able to influence gene
expression with its methylation status; some CpGs are regulatory and others are not. With
so much data, it’s possible that not every CpG is regulatory. Some CpGs could be
functioning as a location for other transcription factors or proteins to bind that may have
functions other than mediating gene expression

118,196

. For many of the genes we

investigated, there was differential methylation in several regions. In our data set, some
genes had antagonistic methylation changes such as hypomethylation at one CpG in the
promoter and hypermethylation at another CpG in the same promoter. It’s been proposed
that methylation may function differently depending on whether it’s in an intron or exon
187

. Further research is needed to answer these questions and to understand the full function

of gene body methylation in the context of low dose arsenic exposure. Clearly, we are at
the beginning of understanding the full function of DNA methylation. Interestingly, recent
studies have linked methylation changes to alterations in alternative splicing patterns
116,118,187

. Our own previous studies implicated all of the genes from our gene expression

experiment as having alternative splicing changes (Supplemental Table 3.7).
The vastness of the data we gained from the Infinium MethylationEPIC BeadChip
Array underscores the complexity of differential DNA methylation in cells, and therefore
the depth of our understanding. For instance, tens of thousands of loci are differentially
methylated in response to low dose arsenic exposure and/or reversal of treatment (Figure
3.3 and Supplemental Figure 3.1); which of them is actually regulatory is the subject of
additional study. However, inorganic arsenic is known to cause detrimental effects through
mechanisms other than epigenetics, such as reactive oxygen species
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10,11,197

. It is also

possible that both mechanisms are working together, enhancing biologic actions to drive
the carcinogenic potential of iAs

198,199

. Further studies to understand this cooperation

would be interesting. In addition to ROS, DNA methylation is also known to interplay
with other epigenetic modifications such histone variants and histone post-translational
modifications

37,63,124

. Because other epigenetic marks are altered in iAs-mediated EMT,

it is plausible that they all work collectively. For example, dysregulation of histones H2B
and H3 has been implicated in iAs-mediated transformation and EMT 63,76. Additionally,
alterations in histone post-translational modifications have been shown in iAs-treated
conditions including upregulation of the repressive mark H3K27me3 and activation of the
mark H3K4me3. It is hypothesized that crosstalk between all of these epigenetic marks –
DNA methylation, histone variants, and histone post-translational modifications – control
the chromatin landscape present in iAs treated cells. For example, DNA methylation and
H3K27me3 are known to be coregulated and both dynamically monitor DNA accessibility
and gene expression

200,201

. Therefore, the full implications of iAs exposure cannot fully

be appreciated without understanding the crosstalk between epigenetic marks.
In conclusion, this study presents genome-wide changes to DNA methylation levels,
as well as changes in gene expression in HeLa cells that were exposed to iAs at chronic
low-dose levels, and also in cells that had the arsenic removed. We found that in many
cases, the changes seen in cells exposed to iAs returned to near NT levels; these regions
may be important in the cellular response to the iAs. However, many genes either do not
revert to NT levels, or show an increased change in DNA methylation and gene expression.
These genes may be involved in the EMT process that drives the carcinogenic effects with
chronic low-dose iAs exposure. Our results provide a platform to develop potential
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epigenetic therapeutics in iAs-mediated carcinogenesis. Such studies could be extended to
other environmental toxicants to enhance the understanding of their impact on the
epigenome and gene expression.
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Table 3.1 Expected methylation patterns for genes investigated for gene expression.
Gene
iAsT Expected
Region iAsT Methylation Expression
CORO1B Promoter Hypomethylation

Upregulated

PPME1 Promoter Hypermethylation Downregulated
PPM1L Gene Body Hypermethylation

iAs-rev
Methylation

iAsT Expected
Expression

NA

NA

NA

NA

Upregulated Hypermethylation Upregulated

CDH12 Gene Body Hypomethylation Downregulated

NA

NA

ARID5B Promoter

NA

NA

Hypomethylation Upregulated

DYNC1I2 Promoter

NA

NA

Hypomethylation Upregulated

PRDX1 Promoter Hypermethylation Downregulated Hypermethylation Downregulated
EPC1

Gene Body

NA

NA

Hypomethylation Downregulated

Methylation patterns identified by the Infinium BeadChip Microarray for each gene that
was investigated for gene expression changes by qRT-PCR; the expected gene expression
patterns based on methylation are presented. Shaded cells indicate that the expected
expression was validated by our qRT-PCR results.
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Table 3.2 Gene Ontology of differentially methylated and differentially expressed genes
(iAsT v. NT).
GO Term
Number of Genes p-value
Intracellular Signal Transduction
36 3.05E-13
Intrinsic Component of Plasma Membrane
36 1.22E-12
Receptor Binding
32 2.93E-11
Cell Development
31 5.74E-11
Tissue Development
32 5.97E-11
Movement of Cell or Subcellular
Component
29 8.81E-11
Regulation of Cell Death
30 5.52E-10
Response to Endogenous Stimulus
29 1.67E-09
Negative Regulation of Response to
Stimulus
28 1.74E-09
Protein Phosphorylation
23 2.43E-09
Gene Ontology terms of differentially methylated and differentially expressed genes
comparing iAsT to NT (270 total genes).
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Table 3.3 Gene Ontology of differentially methylated and differentially expressed genes
(iAs-rev v. NT).
GO Term
Number of Genes p-value
Intrinsic Component of Plasma Membrane
32 3.90E-14
Cell Development
23 7.07E-09
Response to Oxygen Containing Compound
22 1.92E-08
Small Molecule Metabolic Process
25 1.96E-08
Response to Nitrogen Compound
17 4.21E-08
Tissue Development
22 9.99E-08
Neuron Part
20 1.01E-07
Cell Junction
19 1.11E-07
Cytoskeleton
25 1.52E-07
Response to Endogenous Stimulus
21 2.02E-07
Gene Ontology terms of differentially methylated and differentially expressed genes
comparing iAs-rev to NT (187 total genes).
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Table 3.4 Gene Ontology of differentially methylated and differentially expressed genes
(iAs-rev v. iAsT).

GO Term
Intrinsic Component of Plasma Membrane
Receptor Binding
Intracellular Signal Transduction
Regulation of Cell Death
Phosphate Containing Compound Metabolic Process
Negative Regulation of Cell Death
Response to Endogenous Stimulus
Response to Oxygen Containing Compound
Biological Adhesion
Neurogenesis

Number of
Genes

46
38
39
36
42
27
35
34
29
34

p-value
5.76E-17
4.46E-13
6.68E-13
8.35E-12
1.18E-11
2.35E-11
2.39E-11
2.79E-11
4.15E-11
4.16E-11

Gene Ontology terms of differentially methylated and differentially expressed genes
comparing iAs-rev to iAsT (322 total genes).

65

Figure 3.1 Chronic low-dose exposure to iAs and subsequent reversal causes cells to
undergo EMT.

(A). Diagram of Experimental Design. HeLa cells were treated with 0.5µM sodium
arsenite (iAsT) while some were mock treated with dIH2O (NT). After 36 days of iAs
treatment, sodium arsenite was removed from growth media for some treated cells and
replaced with dIH2O (iAs-rev); (B). Western blot analysis of EMT markers show HeLa
cells undergoing iAs-induced EMT. Claudin-1 decreased with treatment, and remained
decreased in the iAs-rev condition. Some markers, like Snail, increased in the iAsT, but
did not return toward NT levels in iAs-rev cells while N-cadherin and Slug increased in
iAsT and returned toward NT levels.
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Figure 3.2 Global DNA methylation levels are increased with 0.5 µM arsenite exposure.

Results from the 5mC-ELISA show that 0.5µM sodium arsenite exposure significantly
increased global DNA methylation levels in HeLa cells. iAsT cells that had exposure
removed (iAs-rev) showed a significant decrease from the iAsT DNA methylation levels;
however, these are still significantly increased from NT levels. ELISA was performed in
triplicate and error bars reflect the SEM of these replicates. Students t-test was performed
for significance (p<0.05); * denotes difference from NT † denotes difference from iAsT
to iAs-rev.

67

Figure 3.3 Methylation EPIC BeadChip Assay reveals global DNA methylation changes
between NT, iAsT, and iAs-rev.

Comparison of loci from NT v. iAsT shows that 67% of loci on the chip are
hypermethylated in iAsT, while only 33% are hypomethylated. Comparison of
methylation loci between NT and iAs-rev shows that 77% of loci are hypermethylated in
iAs-rev while only 23% are hypomethylated. Comparison of iAsT and iAs-rev reveals
that the loci are approximately equal for hyper- and hypomethylation, suggesting that when
iAs is removed many loci return towards NT levels.
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Figure 3.4 DNA methylation patterns show changes both within CGIs and outside of
CGIs during iAs-mediated EMT.

(A). Diagram showing the relationship of CGIs and neighboring regions. CGI is defined
as greater than 50% CG content in at least a 200 base pair region. The north shore is 02000bp upstream of the CGI and north shelf is 2001-4000bp upstream of the CGI. The
south shore is 0-2000bp downstream of the CGI and the south shelf is 2001-4000bp
downstream of the CGI. Open sea regions are more than 4000bp outside of the CGI. (B).
Regional methylation changes between iAsT v. NT (C). Regional methylation changes
between iAs-rev v. NT (D). Regional methylation changes between iAs-rev v. iAsT.
Levels of methylation in shelves and shores stay relatively unchanged between groups and
hyper- or hypomethylation. Prominent methylation changes occur at the CGIs and out in
the open seas.
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Figure 3.5 DNA methylation patterns within gene regulatory regions reveal large changes
within gene bodies, at the 1st exon, and 200-1500bp upstream of start of transcription.

(A). Diagram mapping gene regulatory regions. TSS1500 is 200-1500bp upstream of
transcription start site (TSS), TSS200 is 1-200bp upstream of TSS, 5’UTR is the 5’
untranslated region, 1st exon is the first translated region, gene body includes all other
exons and all introns, and 3’UTR is the 3’ untranslated region where translation ends.
Outside of the TSS1500 and 3’UTR is considered intergenic. (B). Gene Regulatory
methylation differences between iAsT and NT. (C). Gene Regulatory methylation
differences between iAs-rev and NT. (D). Gene Regulatory methylation differences
between iAs-rev and iAsT. Methylation within gene regulatory regions is generally stable
throughout the treatment groups. Gene body and TSS1500 methylation shows the most
variation between hyper- and hypomethylated DMRs.
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Figure 3.6 DNA methylation level changes at promoter associated regions reveal large
changes within the promoter and unclassified regions.

Comparison of DMRs within different promoter types. (A). Regional promoter-associated
methylation differences between iAsT and NT. (B). Regional promoter-associated
methylation differences between iAs-rev and NT. (C). Regional promoter-associated
methylation differences between iAs-rev and iAsT. Promoter methylation changes are
most apparent at promoter associated (dark green) and unclassified regions (purple), which
suggests that iAs targets distinct promoters and regions in methylation changes.
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Figure 3.7 Correlation of differential methylation and gene expression.

(A). Three genes were upregulated with iAs treatment. CORO1B and PPME1 both
increased in expression with iAsT and a further increase was observed in iAs-rev. PPM1L
increased in iAsT, but shifted towards NT levels with iAs-rev. (B). Seven genes were
downregulated with iAs treatment. CDH12 and ARID5B decreased expression levels with
iAsT as well as with iAs-rev. DYNC12, PRDX1 and EPC1 all decreased expression levels
with iAsT, but with iAs-rev the expression levels increased closer to or even above NT
levels. qRT-PCR reactions were performed in triplicate. * indicates a significant change
when iAsT or iAs-rev is compared to NT and † indicates a significant change between
iAsT and iAs-rev with p-value <0.05. Error bars are from triplicate experiments and
represent SEM.
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Supp. Table 3.1 Oncogenic signature of top 4000 DMRs (iAsT v. NT). List of oncogenic
signatures identified for the top 4000 differentially methylated genes for iAsT v. NT.

Description
Genes up-regulated in epithelial kidney cancer cell lines over-expressing an oncogenic form of
KRAS [Gene ID=3845] gene.
Genes up-regulated in four lineages of epithelial cell lines over-expressing an oncogenic form
of KRAS [Gene ID=3845] gene.

# Genes
in
Overlap
(k)

p-value

22

4.23E-13

29

3.49E-12

Genes up-regulated in TIG3 cells (fibroblasts) upon knockdown of BMI1 [Gene ID=648] gene.

22

6.25E-10

Genes up-regulated in DLD1 cells (colon carcinoma) over-expressing LEF1 [Gene ID=51176].
Genes down-regulated in epithelial lung and breast cancer cell lines over-expressing an
oncogenic form of KRAS [Gene ID=3845] gene.
Genes down-regulated in HEK293 cells (kidney fibroblasts) upon knockdown of TP53 [Gene
ID=7157] gene by RNAi.
Genes down-regulated in four lineages of epithelial cell lines over-expressing an oncogenic
form of KRAS [Gene ID=3845] gene.
Genes up-regulated in four lineages of epithelial cell lines over-expressing an oncogenic form
of KRAS [Gene ID=3845] gene.
Genes down-regulated in DAOY cells (medulloblastoma) upon knockdown of PCGF2 [Gene
ID=7703] gene by RNAi.
Genes down-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] MCF7 cells (breast cancer) stably over-expressing constitutively active RAF1 [Gene ID=5894] gene.

21

5.68E-09

24

1.27E-08

17

4.51E-08

23

5.55E-08

16

7.71E-08

16

9.33E-08

19

1.37E-07

Genes up-regulated in neurons.
Genes up-regulated in epithelial kidney cancer cell lines over-expressing an oncogenic form of
KRAS [Gene ID=3845] gene.
Genes up-regulated in BJAB (lymphoma) cells by rapamycin (sirolimus) [PubChem =
6610346].
Genes down-regulated in MEF cells (embryonic fibroblasts) with knockout of SNF5 [Gene
ID=6598] gene.
Genes up-regulated in MEF cells (embryonic fibroblasts) with knockout of NFE2L2 [Gene
ID=4780] gene.
Genes up-regulated in epithelial lung and breast cancer cell lines over-expressing an oncogenic
form of KRAS [Gene ID=3845] gene.
Genes up-regulated in four lineages of epithelial cell lines over-expressing an oncogenic form
of KRAS [Gene ID=3845] gene.
Genes down-regulated in primary thyrocyte cultures in response to cAMP signaling pathway
activation by thyrotropin (TSH).
Genes down-regulated in DLD1 cells (colon carcinoma) over-expressing LEF1 [Gene
ID=51176].
Genes down-regulated in DAOY cells (medulloblastoma) upon knockdown of BMI1 and
PCGF2 [Gene ID=648, 7703] genes by RNAi.
Genes down-regulated in TIG3 cells (fibroblasts) upon knockdown of BMI1 [Gene ID=648]
gene.
Genes down-regulated in SKM-1 cells (AML) after knockdown of STK33 [Gene ID=65975] by
RNAi.
Genes down-regulated in HUVEC cells (endothelium) by treatment with PIGF [Gene
ID=5281].
Genes down-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] MCF7 cells (breast cancer) and long-term adapted for estrogen-independent growth.
Genes down-regulated in epithelial lung and breast cancer cell lines over-expressing an
oncogenic form of KRAS [Gene ID=3845] gene.
Genes down-regulated in HCT116 cells (colon carcinoma) upon knockdown of PTEN [Gene
ID=5728] by RNAi.
Genes down-regulated in epithelial lung cancer cell lines over-expressing KRAS [Gene
ID=3845] gene.
Genes down-regulated in myometrial cells over-expressing a shortened splice form of ATF2
[Gene ID=1386] gene.

13

1.71E-07

16

2.59E-07

17

3.40E-07

16

3.85E-07

29

4.48E-07

21

8.73E-07

22

1.04E-06

17

1.18E-06

17

2.16E-06

14

2.71E-06

16

3.13E-06

20

3.32E-06

16

3.58E-06

16

4.09E-06

21

4.21E-06

14

6.45E-06

14

7.56E-06

16

7.57E-06

Genes down-regulated in myometrial cells over-expressing ATF2 [Gene ID=1386] gene.
Genes up-regulated in HEL cells (erythroleukemia) after knockdown of JAK2 [Gene ID=3717]
gene by RNAi.

16

7.57E-06

16

8.11E-06
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Genes up-regulated in epithelial lung cancer cell lines over-expressing an oncogenic form of
KRAS [Gene ID=3845] gene.
Genes up-regulated in A549 lung carcinoma and M059K glioblastoma cells treated with
dichloroacetate [PubChem=6597].
Genes up-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] and
engineered to express ligand-activatable ERBB2 [Gene ID=2064].

13

8.71E-06

16

9.90E-06

16

9.90E-06

Genes down-regulated in myometrial cells over-expressing ATF2 [Gene ID=1386] gene.

15

1.00E-05

Genes down-regulated in NCI-60 panel of cell lines with mutated TP53 [Gene ID=7157].
Genes down-regulated in DAOY cells (medulloblastoma) upon knockdown of BMI1 [Gene
ID=648] gene by RNAi.
Genes down-regulated in epithelial prostate cancer cell lines over-expressing an oncogenic form
of KRAS [Gene ID=3845] gene.

16

1.06E-05

13

1.09E-05

13

1.09E-05

Genes down-regulated in mouse fibroblasts over-expressing E2F1 [Gene ID=1869] gene.
Genes up-regulated in MOLM-14 cells (AML) with knockdown of HOXA9 [Gene ID=3205]
gene by RNAi vs controls.

16

1.13E-05

16

1.20E-05

Genes up-regulated upon knockdown of PTEN [Gene ID=5728] by RNAi.
Genes up-regulated in epithelial lung cancer cell lines upon over-expression of an oncogenic
form of KRAS [Gene ID=3845] gene and knockdown of TBK1 [Gene ID=29110] gene by
RNAi.

15

1.29E-05

19

1.32E-05

Genes up-regulated in TIG3 cells (fibroblasts) upon knockdown of EED [Gene ID=8726] gene.
Genes down-regulated in SH-SY5Y cells (neuroblastoma) in response to PDGF [Gene ID=]
stimulation after pre-treatment with the ERK inhibitors U0126 and PD98059
[PubChem=3006531, 4713].
Genes down-regulated in primary thyrocyte cultures in response to cAMP signaling pathway
activation by thyrotropin (TSH).
Genes up-regulated in epithelial lung cancer cell lines over-expressing an oncogenic form of
KRAS [Gene ID=3845] gene.
Genes up-regulated in DAOY cells (medulloblastoma) upon knockdown of BMI1 and PCGF2
[Gene ID=648, 7703] genes by RNAi.
Genes down-regulated in epithelial breast cancer cell lines over-expressing an oncogenic form
of KRAS [Gene ID=3845] gene.
Genes up-regulated in four lineages of epithelial cell lines over-expressing an oncogenic form
of KRAS [Gene ID=3845] gene.

15

1.55E-05

13

1.58E-05

16

1.76E-05

13

2.41E-05

13

3.25E-05

13

3.25E-05

13

3.49E-05

Genes up-regulated in mouse fibroblasts over-expressing E2F1 [Gene ID=1869] gene.
Genes down-regulated in Sez-4 cells (T lymphocyte) that were first starved of IL2 [Gene
ID=3558] and then stimulated with IL21 [Gene ID=59067].

15

3.50E-05

14

4.22E-05

Genes down-regulated upon knockdown of PTEN [Gene ID=5728] by RNAi.
Genes down-regulated in four lineages of epithelial cell lines over-expressing an oncogenic
form of KRAS [Gene ID=3845] gene.
Genes up-regulated in TIG3 cells (fibroblasts) upon knockdown of SUZ12 [Gene ID=23512]
gene.
Genes up-regulated in epithelial prostate cancer cell lines over-expressing an oncogenic form of
KRAS [Gene ID=3845] gene.
Genes up-regulated in HCT116 cells (colon carcinoma) upon knockdown of PTEN [Gene
ID=5728] by RNAi.
Genes up-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] MCF-7
cells (breast cancer) stably over-expressing constitutively active MAP2K1 [Gene ID=5604]
gene.

14

4.22E-05

19

4.72E-05

15

4.73E-05

12

4.88E-05

12

4.88E-05

15

5.32E-05

Genes down-regulated in retina cells from CRX [Gene ID=1406] knockout mice.
Genes down-regulated in DAOY cells (medulloblastoma) upon knockdown of ALK [Gene
ID=238] gene by RNAi.

12

6.53E-05

12

6.82E-05

Genes up-regulated in late serum response of CRL 2091 cells (foreskin fibroblasts).
Genes up-regulated in BJAB (lymphoma) cells by rapamycin (sirolimus) [PubChem =
6610346].
Genes down-regulated in four lineages of epithelial cell lines over-expressing an oncogenic
form of KRAS [Gene ID=3845] gene.
Genes up-regulated in MCF-7 cells (breast cancer) over-expressing a mutant K112E form of
CCND1 [Gene ID=595] gene.
Genes up-regulated in epithelial lung and breast cancer cell lines over-expressing an oncogenic
form of KRAS [Gene ID=3845] gene.
Genes up-regulated in epithelial lung and breast cancer cell lines over-expressing an oncogenic
form of KRAS [Gene ID=3845] gene.

13

7.11E-05

14

9.37E-05

12

1.22E-04

14

1.39E-04

12

1.39E-04

18

1.40E-04
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Genes up-regulated in HUVEC cells (endothelium) by treatment with PIGF [Gene ID=5281].
Genes down-regulated in TIG3 cells (fibroblasts) upon knockdown of SUZ12 [Gene ID=23512]
gene.

14

1.47E-04

14

1.47E-04

Genes up-regulated in JNK inhibitor-treated (SP600125[PubChem=8515]) keratinocytes.
Genes down-regulated in myometrial cells over-expressing a shortened splice form of ATF2
[Gene ID=1386] gene.
Genes up-regulated during early stages of differentiation of embryoid bodies from V6.5
embryonic stem cells.
Genes down-regulated in NOMO-1 cells (AML) after knockdown of STK33 [Gene ID=65975]
by RNAi.
Genes down-regulated in HUVEC cells (endothelium) by treatment with PIGF [Gene
ID=5281].
Genes up-regulated in MCF10A cells (breast cancer) upon knockdown of BRCA1 [Gene
ID=672] gene by RNAi.
Genes down-regulated in MCF10A cells (breast cancer) upon knockdown of RBBP8 [Gene
ID=RBBP8] gene by RNAi.
Genes down-regulated in HEK293 cells (kidney fibroblasts) upon knockdown of RELA [Gene
ID=5970] gene by RNAi.
Genes up-regulated in CEM-C1 cells (T-CLL) by rapamycin (sirolimus) [PubChem =
6610346], an mTOR pathway inhibitor.
Genes up-regulated during late stages of differentiation of embryoid bodies from J1 embryonic
stem cells.
Genes down-regulated in BJAB (lymphoma) cells by rapamycin (sirolimus) [PubChem =
6610346].
Genes up-regulated in MOLT4 cells (T-ALL) by DAPT [PubChem=16219261], an inhibitor of
NOTCH signaling pathway.
Genes up-regulated in TIG3 cells (fibroblasts) upon knockdown of SUZ12 [Gene ID=23512]
gene.
Genes up-regulated in primary thyrocyte cultures in response to cAMP signaling pathway
activation by thyrotropin (TSH).
Genes up-regulated in DAOY cells (medulloblastoma) upon knockdown of BMI1 and PCGF2
[Gene ID=648, 7703] genes by RNAi.
Genes up-regulated in epithelial lung and breast cancer cell lines over-expressing an oncogenic
form of KRAS [Gene ID=3845] gene.

14

1.56E-04

13

1.65E-04

13

1.65E-04

18

1.66E-04

14

1.73E-04

11

1.90E-04

11

1.90E-04

11

1.90E-04

14

1.93E-04

13

2.03E-04

13

2.03E-04

13

2.25E-04

13

2.37E-04

14

2.38E-04

11

2.43E-04

11

2.43E-04

Genes up-regulated in DLD1 cells (colon carcinoma) over-expressing LEF1 [Gene ID=51176].
Genes up-regulated during early stages of differentiation of embryoid bodies from V6.5
embryonic stem cells.
Genes down-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] and
engineered to express ligand-activatable EGFR [Gene ID=1956].
Genes up-regulated in HUVEC cells (endothelium) by treatment with VEGFA [Gene
ID=7422].
Genes down-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] and
engineered to express ligand-activatable ERBB2 [Gene ID=2064].
Genes up-regulated by everolimus [PubChem = 6442177] in mouse prostate tissue
transgenically expressing human AKT1 gene [Gene ID=207] vs untreated controls.
Genes down-regulated during late stages of differentiation of embryoid bodies from J1
embryonic stem cells.
Genes down-regulated in SKM-1 cells (AML) after knockdown of STK33 [Gene ID=65975] by
RNAi.
Genes down-regulated in Sez-4 cells (T lymphocyte) that were first starved of IL2 [Gene
ID=3558] and then stimulated with IL21 [Gene ID=59067].
Genes down-regulated in CD34+ hematopoietic progenitor cells after knockdown of RPS14
[Gene ID=6208] by RNAi.
Genes up-regulated in epithelial lung cancer cell lines upon over-expression of an oncogenic
form of KRAS [Gene ID=3845] gene and knockdown of TBK1 [Gene ID=29110] gene by
RNAi.
Genes up-regulated during late stages of differentiation of embryoid bodies from J1 embryonic
stem cells.
Genes up-regulated during late stages of differentiation of embryoid bodies from V6.5
embryonic stem cells.

13

2.49E-04

12

2.52E-04

13

2.61E-04

13

2.61E-04

13

2.75E-04

13

3.58E-04

13

3.97E-04

17

4.10E-04

13

4.18E-04

13

4.18E-04

17

4.44E-04

13

5.11E-04

12

6.88E-04

Genes up-regulated in HUVEC cells (endothelium) by treatment with PIGF [Gene ID=5281].
Genes down-regulated in CEM-C1 cells (T-CLL) by rapamycin (sirolimus) [PubChem =
6610346], an mTOR pathway inhibitor.
Genes down-regulated in SH-SY5Y cells (neuroblastoma) in response to PDGF [Gene ID=]
stimulation.

12

7.20E-04

12

7.89E-04

10

8.22E-04
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Supp. Table 3.2 Oncogenic signature of top 4000 DMRs (iAs-rev v. NT). List of
oncogenic signatures identified for the top 4000 differentially methylated genes for iAsrev v. NT.
# Genes
in
Overlap
(k)

Description

p-value

Genes up-regulated in BJAB (lymphoma) cells by rapamycin (sirolimus) [PubChem = 6610346].
Genes down-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] MCF-7
cells (breast cancer) stably over-expressing constitutively active RAF1 [Gene ID=5894] gene.
Genes up-regulated in four lineages of epithelial cell lines over-expressing an oncogenic form of
KRAS [Gene ID=3845] gene.
Genes up-regulated in epithelial kidney cancer cell lines over-expressing an oncogenic form of
KRAS [Gene ID=3845] gene.
Genes up-regulated in four lineages of epithelial cell lines over-expressing an oncogenic form of
KRAS [Gene ID=3845] gene.
Genes down-regulated in primary thyrocyte cultures in response to cAMP signaling pathway
activation by thyrotropin (TSH).

23

7.27E-11

24

2.45E-10

26

5.74E-09

18

1.01E-08

18

1.12E-08

21

1.27E-08

Genes up-regulated by everolimus [PubChem = 6442177] in prostate tissue.
Genes down-regulated during early stages of differentiation of embryoid bodies from V6.5
embryonic stem cells.
Genes up-regulated in epithelial lung and breast cancer cell lines over-expressing an oncogenic
form of KRAS [Gene ID=3845] gene.
Genes down-regulated in NOMO-1 and SKM-1 cells (AML) after knockdown of STK33 [Gene
ID=65975] by RNAi.
Genes up-regulated in TIG3 cells (fibroblasts) upon knockdown of SUZ12 [Gene ID=23512]
gene.
Genes down-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] and
engineered to express ligand-activatable EGFR [Gene ID=1956].
Genes down-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] MCF-7
cells (breast cancer) stably over-expressing constitutively active MAP2K1 [Gene ID=5604] gene.
Genes down-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] and
engineered to express ligand-activatable ERBB2 [Gene ID=2064].

19

9.24E-08

18

1.44E-07

25

1.46E-07

25

1.56E-07

19

1.87E-07

20

1.93E-07

20

1.93E-07

20

2.10E-07

Genes up-regulated in neurons.
Genes down-regulated in MEF cells (embryonic fibroblasts) with knockout of SNF5 [Gene
ID=6598] gene.
Genes down-regulated in DAOY cells (medulloblastoma) upon knockdown of BMI1 and PCGF2
[Gene ID=648, 7703] genes by RNAi.
Genes up-regulated in MEF cells (embryonic fibroblasts) with knockout of NFE2L2 [Gene
ID=4780] gene.
Genes up-regulated during late stages of differentiation of embryoid bodies from J1 embryonic
stem cells.

14

2.82E-07

17

3.64E-07

16

4.11E-07

31

5.37E-07

19

5.74E-07

Genes up-regulated in neurons.

13

6.48E-07

Genes up-regulated in TIG3 cells (fibroblasts) upon knockdown of EZH2 [Gene ID=2146] gene.
Genes up-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] MCF-7
cells (breast cancer) stably over-expressing constitutively active MAP2K1 [Gene ID=5604] gene.
Genes up-regulated in epithelial lung and breast cancer cell lines over-expressing an oncogenic
form of KRAS [Gene ID=3845] gene.
Genes down-regulated in DAOY cells (medulloblastoma) upon knockdown of PCGF2 [Gene
ID=7703] gene by RNAi.
Genes up-regulated in epithelial lung and breast cancer cell lines over-expressing an oncogenic
form of KRAS [Gene ID=3845] gene.
Genes up-regulated in four lineages of epithelial cell lines over-expressing an oncogenic form of
KRAS [Gene ID=3845] gene.

19

7.89E-07

19

8.52E-07

16

1.12E-06

16

1.47E-06

22

1.54E-06

23

1.81E-06

Genes up-regulated in HUVEC cells (endothelium) by treatment with PIGF [Gene ID=5281].
Genes up-regulated in TIG3 cells (fibroblasts) upon knockdown of SUZ12 [Gene ID=23512]
gene.

18

2.46E-06

18

3.07E-06

Genes up-regulated in DLD1 cells (colon carcinoma) over-expressing LEF1 [Gene ID=51176].
Genes up-regulated in MEF cells (embryonic fibroblasts) with knockout of NFE2L2 [Gene
ID=4780] gene.

18

3.31E-06

31

3.46E-06

76

Genes down-regulated in TIG3 cells (fibroblasts) upon knockdown of EZH2 [Gene ID=2146]
gene.
Genes down-regulated in DAOY cells (medulloblastoma) upon knockdown of BMI1 [Gene
ID=648] gene by RNAi.
Genes up-regulated in epithelial kidney cancer cell lines over-expressing an oncogenic form of
KRAS [Gene ID=3845] gene.
Genes down-regulated in SKM-1 cells (AML) after knockdown of STK33 [Gene ID=65975] by
RNAi.
Genes down-regulated in epithelial lung and breast cancer cell lines over-expressing an
oncogenic form of KRAS [Gene ID=3845] gene.
Genes up-regulated in MCF10A cells (breast cancer) upon knockdown of BRCA1 [Gene
ID=672] gene by RNAi.
Genes up-regulated in SKM-1 cells (AML) after knockdown of STK33 [Gene ID=65975] by
RNAi.
Genes down-regulated in myometrial cells over-expressing a shortened splice form of ATF2
[Gene ID=1386] gene.
Genes up-regulated in epithelial lung and breast cancer cell lines over-expressing an oncogenic
form of KRAS [Gene ID=3845] gene.
Genes up-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] and
engineered to express ligand-activatable ERBB2 [Gene ID=2064].
Genes up-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] and
engineered to express ligand-activatable EGFR [Gene ID=1956].
Genes down-regulated in MCF-7 cells (breast cancer) over-expressing CCND1 [Gene ID=595]
gene.
Genes down-regulated in TIG3 cells (fibroblasts) upon knockdown of BMI1 [Gene ID=648]
gene.
Genes up-regulated in MOLT4 cells (T-ALL) by DAPT [PubChem=16219261], an inhibitor of
NOTCH signaling pathway.

17

3.78E-06

15

4.92E-06

15

5.35E-06

21

5.47E-06

21

5.77E-06

14

6.37E-06

22

7.26E-06

17

7.53E-06

14

8.81E-06

17

9.96E-06

17

1.14E-05

16

1.28E-05

16

1.36E-05

16

1.45E-05

Genes down-regulated in HUVEC cells (endothelium) by treatment with PIGF [Gene ID=5281].
Genes up-regulated in primary keratinocytes from RB1 and RBL1 [Gene ID=5925, 5933] skin
specific knockout mice.
Genes down-regulated in SKM-1 cells (AML) after knockdown of STK33 [Gene ID=65975] by
RNAi.
Genes down-regulated during early stages of differentiation of embryoid bodies from J1
embryonic stem cells.
Genes up-regulated in NOMO-1 and SKM-1 cells (AML) after knockdown of STK33 [Gene
ID=65975] by RNAi.
Genes down-regulated in DAOY cells (medulloblastoma) upon knockdown of BMI1 and PCGF2
[Gene ID=648, 7703] genes by RNAi.
Genes up-regulated in granule cell neuron precursors (GCNPs) after stimulation with Shh for
24h.
Genes up-regulated in HEL cells (erythroleukemia) after knockdown of JAK2 [Gene ID=3717]
gene by RNAi.
Genes down-regulated in granule cell neuron precursors (GCNPs) after stimulation with Shh for
3h.
Genes up-regulated during late stages of differentiation of embryoid bodies from V6.5 embryonic
stem cells.
Genes down-regulated in DAOY cells (medulloblastoma) upon knockdown of BMI1 [Gene
ID=648] gene by RNAi.

16

1.55E-05

14

1.61E-05

21

2.10E-05

15

2.35E-05

21

2.71E-05

14

2.79E-05

15

3.04E-05

16

3.13E-05

15

3.36E-05

16

3.56E-05

13

3.73E-05

Genes down-regulated in JNK inhibitor-treated (SP600125[PubChem=8515]) keratinocytes.
Genes down-regulated in TIG3 cells (fibroblasts) upon knockdown of BMI1 [Gene ID=648]
gene.
Genes down-regulated in DAOY cells (medulloblastoma) upon knockdown of PCGF2 [Gene
ID=7703] gene by RNAi.
Genes up-regulated in primary epithelial breast cancer cell culture over-expressing E2F3 [Gene
ID=1871] gene.
Genes down-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] MCF-7
cells (breast cancer) and long-term adapted for estrogen-independent growth.

16

3.79E-05

16

4.04E-05

13

4.96E-05

16

5.18E-05

16

5.18E-05

Genes up-regulated in myometrial cells over-expressing ATF2 [Gene ID=1386] gene.
Genes down-regulated in MCF-7 cells (breast cancer) over-expressing a mutant K112E form of
CCND1 [Gene ID=595] gene.
Genes down-regulated in four lineages of epithelial cell lines over-expressing an oncogenic form
of KRAS [Gene ID=3845] gene.
Genes down-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] MCF-7
cells (breast cancer) and long-term adapted for estrogen-independent growth.

15

5.29E-05

15

5.96E-05

19

6.19E-05

15

6.69E-05
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Genes down-regulated in four lineages of epithelial cell lines over-expressing an oncogenic form
of KRAS [Gene ID=3845] gene.
Genes up-regulated in MCF10A cells (breast cancer) upon knockdown of BRCA1 [Gene
ID=672] gene by RNAi.
Genes down-regulated in NOMO-1 cells (AML) after knockdown of STK33 [Gene ID=65975]
by RNAi.
Genes up-regulated in NOMO-1 cells (AML) after knockdown of STK33 [Gene ID=65975] by
RNAi.
Genes up-regulated by everolimus [PubChem = 6442177] in mouse prostate tissue transgenically
expressing human AKT1 gene [Gene ID=207] vs untreated controls.
Genes down-regulated during late stages of differentiation of embryoid bodies from J1
embryonic stem cells.
Genes down-regulated in Sez-4 cells (T lymphocyte) that were first starved of IL2 [Gene
ID=3558] and then stimulated with IL21 [Gene ID=59067].
Genes down-regulated in MCF10A cells (breast cancer) upon knockdown of RBBP8 [Gene
ID=RBBP8] gene by RNAi.
Genes down-regulated in MCF-7 cells (breast cancer) over-expressing CCND1 [Gene ID=595]
gene.

20

6.79E-05

13

7.47E-05

20

7.82E-05

20

8.58E-05

15

8.92E-05

15

1.01E-04

15

1.07E-04

12

1.29E-04

15

1.35E-04

Genes up-regulated in early serum response of CRL 2091 cells (foreskin fibroblasts).
Genes up-regulated in CD34+ hematopoietic progenitor cells after knockdown of RPS14 [Gene
ID=6208] by RNAi.
Genes down-regulated in MCF10A cells (breast cancer) upon knockdown of BRCA1 [Gene
ID=672] gene by RNAi.
Genes down-regulated in TIG3 cells (fibroblasts) upon knockdown of EED [Gene ID=8726]
gene.

13

1.41E-04

15

1.43E-04

12

1.48E-04

15

1.52E-04

Genes up-regulated in late serum response of CRL 2091 cells (foreskin fibroblasts).
Genes up-regulated in MOLM-14 cells (AML) with knockdown of HOXA9 [Gene ID=3205]
gene by RNAi vs controls.

14

1.54E-04

15

1.61E-04

Genes up-regulated in NCI-60 panel of cell lines with mutated TP53 [Gene ID=7157].
Genes down-regulated in Sez-4 cells (T lymphocyte) that were first starved of IL2 [Gene
ID=3558] and then stimulated with IL2 [Gene ID=3558].
Genes down-regulated in NOMO-1 and SKM-1 cells (AML) after knockdown of STK33 [Gene
ID=65975] by RNAi.

15

1.61E-04

15

1.80E-04

18

1.88E-04

Genes down-regulated in a panel of epithelial cell lines by TGFB1 [Gene ID=7040].
Genes up-regulated in myometrial cells over-expressing a shortened splice form of ATF2 [Gene
ID=1386] gene.

14

1.92E-04

14

2.03E-04

Genes down-regulated in mouse fibroblasts over-expressing E2F1 [Gene ID=1869] gene.
Genes down-regulated in NOMO-1 cells (AML) after knockdown of STK33 [Gene ID=65975]
by RNAi.
Genes down-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] and
engineered to express ligand-activatable EGFR [Gene ID=1956].
Genes up-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] MCF-7
cells (breast cancer) stably over-expressing constitutively active RAF1 [Gene ID=5894] gene.

14

2.03E-04

18

2.13E-04

14

2.38E-04

14

2.38E-04

Genes up-regulated in HUVEC cells (endothelium) by treatment with VEGFA [Gene ID=7422].
Genes down-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] and
engineered to express ligand-activatable ERBB2 [Gene ID=2064].
Genes up-regulated in primary keratinocytes from RB1 [Gene ID=5925] skin specific knockout
mice.
Genes down-regulated in mouse prostate by transgenic expression of human AKT1 gene [Gene
ID=207] vs controls.
Genes down-regulated in myometrial cells over-expressing a shortened splice form of ATF2
[Gene ID=1386] gene.
Genes down-regulated in Sez-4 cells (T lymphocyte) that were first starved of IL2 [Gene
ID=3558] and then stimulated with IL21 [Gene ID=59067].
Genes up-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] MCF-7
cells (breast cancer) and long-term adapted for estrogen-independent growth.
Genes up-regulated in epithelial lung cancer cell lines over-expressing KRAS [Gene ID=3845]
gene.

14

2.38E-04

14

2.51E-04

11

4.03E-04

13

5.07E-04

13

5.07E-04

13

5.07E-04

13

5.89E-04

11

6.15E-04

Genes down-regulated in NCI-60 panel of cell lines with mutated TP53 [Gene ID=7157].

13

6.50E-04
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Supp. Table 3.3 Oncogenic signature of top 4000 DMRs (iAs-rev v. iAsT). List of
oncogenic signatures identified for the top 4000 differentially methylated genes for iAsrev v. iAsT.

Description
Genes up-regulated in epithelial kidney cancer cell lines over-expressing an oncogenic form of
KRAS [Gene ID=3845] gene.
Genes up-regulated in four lineages of epithelial cell lines over-expressing an oncogenic form of
KRAS [Gene ID=3845] gene.

# Genes
in
Overlap
(k)

p-value

21

3.08E-13

24

8.91E-10

Genes up-regulated in neurons.
Genes down-regulated in HEK293 cells (kidney fibroblasts) upon knockdown of TP53 [Gene
ID=7157] gene by RNAi.
Genes up-regulated in epithelial kidney cancer cell lines over-expressing an oncogenic form of
KRAS [Gene ID=3845] gene.

14

4.32E-09

18

7.35E-09

17

4.51E-08

Genes down-regulated in myometrial cells over-expressing ATF2 [Gene ID=1386] gene.
Genes up-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] MCF-7
cells (breast cancer) stably over-expressing constitutively active MAP2K1 [Gene ID=5604] gene.
Genes up-regulated in HCT116 cells (colon carcinoma) upon knockdown of PTEN [Gene
ID=5728] by RNAi.

17

7.45E-08

17

1.47E-07

14

4.22E-07

Genes up-regulated in TIG3 cells (fibroblasts) upon knockdown of BMI1 [Gene ID=648] gene.

18

4.75E-07

Genes down-regulated in JNK inhibitor-treated (SP600125[PubChem=8515]) keratinocytes.
Genes down-regulated in TIG3 cells (fibroblasts) upon knockdown of EZH2 [Gene ID=2146]
gene.
Genes up-regulated in HCT116 cells (colon carcinoma) upon knockdown of PTEN [Gene
ID=5728] by RNAi.
Genes up-regulated in epithelial lung and breast cancer cell lines over-expressing an oncogenic
form of KRAS [Gene ID=3845] gene.
Genes up-regulated in MCF10A cells (breast cancer) upon knockdown of BRCA1 [Gene
ID=672] gene by RNAi.
Genes up-regulated in MOLT4 cells (T-ALL) by DAPT [PubChem=16219261], an inhibitor of
NOTCH signaling pathway.
Genes down-regulated in epithelial lung cancer cell lines over-expressing an oncogenic form of
KRAS [Gene ID=3845] gene.
Genes up-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] and
engineered to express ligand-activatable EGFR [Gene ID=1956].
Genes up-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] MCF-7
cells (breast cancer) stably over-expressing constitutively active MAP2K1 [Gene ID=5604] gene.
Genes down-regulated in DAOY cells (medulloblastoma) upon knockdown of BMI1 and PCGF2
[Gene ID=648, 7703] genes by RNAi.
Genes down-regulated in DAOY cells (medulloblastoma) upon knockdown of PCGF2 [Gene
ID=7703] gene by RNAi.

16

5.45E-07

18

6.46E-07

15

1.17E-06

19

1.89E-06

13

2.14E-06

17

2.68E-06

13

2.93E-06

15

3.12E-06

17

3.31E-06

13

3.41E-06

13

3.68E-06

Genes up-regulated in BJAB (lymphoma) cells by rapamycin (sirolimus) [PubChem = 6610346].
Genes up-regulated in four lineages of epithelial cell lines over-expressing an oncogenic form of
KRAS [Gene ID=3845] gene.
Genes down-regulated in DAOY cells (medulloblastoma) upon knockdown of ALK [Gene
ID=238] gene by RNAi.

16

5.75E-06

14

7.56E-06

14

8.85E-06

Genes down-regulated in late serum response of CRL 2091 cells (foreskin fibroblasts).
Genes down-regulated in retina cells from CRX and NRL [Gene ID=1406, 4901] double
knockout mice.
Genes down-regulated in myometrial cells over-expressing a shortened splice form of ATF2
[Gene ID=1386] gene.
Genes up-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] and
engineered to express ligand-activatable EGFR [Gene ID=1956].

15

1.00E-05

13

1.01E-05

14

1.01E-05

16

1.13E-05

Genes down-regulated in HUVEC cells (endothelium) by treatment with PIGF [Gene ID=5281].
Genes up-regulated in TIG3 cells (fibroblasts) upon knockdown of SUZ12 [Gene ID=23512]
gene.
Genes up-regulated during late stages of differentiation of embryoid bodies from V6.5 embryonic
stem cells.

16

1.20E-05

16

1.20E-05

14

1.21E-05
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Genes up-regulated in TIG3 cells (fibroblasts) upon knockdown of EZH2 [Gene ID=2146] gene.

16

1.28E-05

Genes up-regulated upon knockdown of PTEN [Gene ID=5728] by RNAi.
Genes up-regulated in four lineages of epithelial cell lines over-expressing an oncogenic form of
KRAS [Gene ID=3845] gene.
Genes up-regulated in MOLT4 cells (T-ALL) by DAPT [PubChem=16219261], an inhibitor of
NOTCH signaling pathway.
Genes down-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] MCF-7
cells (breast cancer) stably over-expressing constitutively active RAF1 [Gene ID=5894] gene.

14

1.29E-05

20

1.31E-05

14

1.45E-05

14

1.53E-05

Genes up-regulated in DLD1 cells (colon carcinoma) over-expressing LEF1 [Gene ID=51176].
Genes up-regulated in four lineages of epithelial cell lines over-expressing an oncogenic form of
KRAS [Gene ID=3845] gene.
Genes down-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] MCF-7
cells (breast cancer) and long-term adapted for estrogen-independent growth.
Genes down-regulated during early stages of differentiation of embryoid bodies from J1
embryonic stem cells.
Genes up-regulated in epithelial lung cancer cell lines over-expressing an oncogenic form of
KRAS [Gene ID=3845] gene.
Genes down-regulated in epithelial lung and breast cancer cell lines over-expressing an
oncogenic form of KRAS [Gene ID=3845] gene.
Genes down-regulated during late stages of differentiation of embryoid bodies from J1
embryonic stem cells.
Genes down-regulated in DAOY cells (medulloblastoma) upon knockdown of BMI1 [Gene
ID=648] gene by RNAi.
Genes down-regulated in Sez-4 cells (T lymphocyte) that were first starved of IL2 [Gene
ID=3558] and then stimulated with IL21 [Gene ID=59067].

14

1.63E-05

12

1.70E-05

14

1.72E-05

15

1.85E-05

13

2.41E-05

17

2.85E-05

15

2.91E-05

13

3.02E-05

15

3.09E-05

Genes down-regulated in small intestine in PRKCA [Gene ID=5578] knockout mice.
Genes down-regulated in epithelial lung cancer cell lines over-expressing KRAS [Gene
ID=3845] gene.
Genes up-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] MCF-7
cells (breast cancer) and long-term adapted for estrogen-independent growth.
Genes up-regulated in SH-SY5Y cells (neuroblastoma) in response to PDGF [Gene ID=]
stimulation after pre-treatment with the ERK inhibitors U0126 and PD98059
[PubChem=3006531, 4713].
Genes down-regulated in MCF-7 cells (breast cancer) over-expressing CCND1 [Gene ID=595]
gene.

14

3.47E-05

13

3.49E-05

15

3.72E-05

13

3.75E-05

15

3.95E-05

Genes down-regulated in NCI-60 panel of cell lines with mutated TP53 [Gene ID=7157].
Genes down-regulated during early stages of differentiation of embryoid bodies from V6.5
embryonic stem cells.
Genes up-regulated in epithelial lung cancer cell lines upon over-expression of an oncogenic
form of KRAS [Gene ID=3845] gene and knockdown of TBK1 [Gene ID=29110] gene by RNAi.
Genes up-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] and
engineered to express ligand-activatable ERBB2 [Gene ID=2064].
Genes down-regulated in TIG3 cells (fibroblasts) upon knockdown of BMI1 [Gene ID=648]
gene.
Genes up-regulated in CD34+ hematopoietic progenitor cells after knockdown of RPS14 [Gene
ID=6208] by RNAi.
Genes down-regulated in MCF10A cells (breast cancer) upon knockdown of RBBP8 [Gene
ID=RBBP8] gene by RNAi.
Genes down-regulated in primary thyrocyte cultures in response to cAMP signaling pathway
activation by thyrotropin (TSH).
Genes down-regulated in DAOY cells (medulloblastoma) upon knockdown of BMI1 [Gene
ID=648] gene by RNAi.
Genes down-regulated in epithelial prostate cancer cell lines over-expressing an oncogenic form
of KRAS [Gene ID=3845] gene.
Genes up-regulated by everolimus [PubChem = 6442177] in mouse prostate tissue transgenically
expressing human AKT1 gene [Gene ID=207] vs untreated controls.
Genes up-regulated in MCF10A cells (breast cancer) upon knockdown of BRCA1 [Gene
ID=672] gene by RNAi.
Genes up-regulated in HEL cells (erythroleukemia) after knockdown of JAK2 [Gene ID=3717]
gene by RNAi.
Genes down-regulated in HCT116 cells (colon carcinoma) upon knockdown of PTEN [Gene
ID=5728] by RNAi.
Genes up-regulated in DAOY cells (medulloblastoma) upon knockdown of BMI1 and PCGF2
[Gene ID=648, 7703] genes by RNAi.

15

4.20E-05

14

4.79E-05

19

4.94E-05

13

5.61E-05

13

5.92E-05

13

5.92E-05

11

6.09E-05

15

6.69E-05

11

7.38E-05

11

7.38E-05

14

9.93E-05

12

1.07E-04

14

1.25E-04

12

1.31E-04

12

1.39E-04
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Genes up-regulated in epithelial lung and breast cancer cell lines over-expressing an oncogenic
form of KRAS [Gene ID=3845] gene.
Genes down-regulated in SKM-1 cells (AML) after knockdown of STK33 [Gene ID=65975] by
RNAi.
Genes down-regulated in epithelial lung and breast cancer cell lines over-expressing an
oncogenic form of KRAS [Gene ID=3845] gene.
Genes up-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] and
engineered to express ligand-activatable ERBB2 [Gene ID=2064].
Genes down-regulated in TIG3 cells (fibroblasts) upon knockdown of BMI1 [Gene ID=648]
gene.

18

1.40E-04

18

1.40E-04

18

1.46E-04

14

1.47E-04

14

1.56E-04

Genes up-regulated in a panel of epithelial cell lines by TGFB1 [Gene ID=7040].
Genes down-regulated in A549 lung carcinoma and M059K glioblastoma cells treated with
dichloroacetate [PubChem=6597].

14

1.56E-04

14

1.64E-04

Genes down-regulated in mouse fibroblasts over-expressing E2F1 [Gene ID=1869] gene.
Genes up-regulated during early stages of differentiation of embryoid bodies from V6.5
embryonic stem cells.
Genes down-regulated in MCF-7 cells (breast cancer) over-expressing a mutant K112E form of
CCND1 [Gene ID=595] gene.

14

1.64E-04

13

1.65E-04

14

1.73E-04

Genes up-regulated in NCI-60 panel of cell lines with mutated TP53 [Gene ID=7157].
Genes down-regulated during late stages of differentiation of embryoid bodies from J1
embryonic stem cells.
Genes down-regulated in Sez-4 cells (T lymphocyte) that were first starved of IL2 [Gene
ID=3558] and then stimulated with IL21 [Gene ID=59067].

14

1.73E-04

12

1.77E-04

12

1.86E-04

Genes down-regulated in retina cells from CRX [Gene ID=1406] knockout mice.
Genes up-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] MCF-7
cells (breast cancer) stably over-expressing constitutively active RAF1 [Gene ID=5894] gene.

10

1.88E-04

14

1.93E-04

Genes up-regulated in HUVEC cells (endothelium) by treatment with VEGFA [Gene ID=7422].

14

1.93E-04

Genes up-regulated in retina cells from CRX [Gene ID=1406] knockout mice.
Genes down-regulated in MCF-7 cells (breast cancer) over-expressing CCND1 [Gene ID=595]
gene.

10

2.12E-04

12

2.27E-04

Genes up-regulated in HUVEC cells (endothelium) by treatment with PIGF [Gene ID=5281].
Genes up-regulated in primary thyrocyte cultures in response to cAMP signaling pathway
activation by thyrotropin (TSH).
Genes up-regulated in primary epithelial breast cancer cell culture over-expressing E2F3 [Gene
ID=1871] gene.
Genes down-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] and
engineered to express ligand-activatable EGFR [Gene ID=1956].
Genes down-regulated in SH-SY5Y cells (neuroblastoma) in response to PDGF [Gene ID=]
stimulation.
Genes down-regulated in SH-SY5Y cells (neuroblastoma) in response to PDGF [Gene ID=]
stimulation after pre-treatment with the ERK inhibitors U0126 and PD98059
[PubChem=3006531, 4713].
Genes up-regulated in granule cell neuron precursors (GCNPs) after stimulation with Shh for
24h.
Genes down-regulated in Sez-4 cells (T lymphocyte) that were first starved of IL2 [Gene
ID=3558] and then stimulated with IL15 [Gene ID=3600].
Genes down-regulated in MEF cells (embryonic fibroblasts) with knockout of SNF5 [Gene
ID=6598] gene.
Genes down-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] MCF-7
cells (breast cancer) stably over-expressing constitutively active MAP2K1 [Gene ID=5604] gene.
Genes up-regulated in primary thyrocyte cultures in response to cAMP signaling pathway
activation by thyrotropin (TSH).

12

2.27E-04

14

2.38E-04

12

2.87E-04

12

2.87E-04

10

3.01E-04

10

4.41E-04

11

5.92E-04

11

8.08E-04

10

9.29E-04

11

1.04E-03

11

1.22E-03

Genes down-regulated in late serum response of CRL 2091 cells (foreskin fibroblasts).

10

1.22E-03

Genes up-regulated in small intestine in PRKCA [Gene ID=5578] knockout mice.

10

1.22E-03
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Supp. Table 3.4 Gene Ontology of differentially methylated and differentially expressed
genes (iAsT v. NT). Gene ontology terms of both hypomethylated (132 genes) and
hypermethylated (182 genes) genes comparing iAsT to NT.
GO Term

Number of Genes
Hypomethylation (132 Genes)
Intracellular Signal Transduction
23
Intrinsic Component of Plasma Membrane
22
Negative Regulation of Cell Death
16
Regulation of Cell Death
20
Protein Phosphorylation
16
Endoplasmic Reticulum
20
Homeostatic Process
18
Phosphorylation
17
Cellular Homeostasis
13
Neurogenesis
18
Hypermethylation (182 Genes)
Intracellular Signal Transduction
24
Movement of Cell or Subcellular Component
20
Kinase Binding
14
Cell Development
21
Receptor Binding
21
Positive Regulation of Molecular Function
23
Positive Regulation of Transporter Activity
6
System Process
22
Tissue Development
20
Cell Projection Organization
15
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p-value
3.71E-11
5.89E-10
1.99E-09
2.88E-09
6.10E-09
1.60E-08
2.22E-08
3.80E-08
4.15E-08
4.54E-08
2.22E-09
3.49E-08
4.47E-08
4.51E-08
8.03E-08
1.15E-07
3.35E-07
4.46E-07
5.60E-07
9.68E-07

Supp. Table 3.5 Gene Ontology of differentially methylated and differentially expressed
genes (iAs-rev v. NT). Gene ontology terms of both hypomethylated (67 genes) and
hypermethylated (141 genes) genes comparing iAs-rev to NT.
GO Term

Number of Genes
Hypomethylation (67 Genes)
Cell Development
13
Intrinsic Component of Plasma Membrane
13
Endoplasmic Reticulum
12
Neurogenesis
11
Neuron Differentiation
9
Response to Organic Cyclic Compound
9
Ion Transport
10
Amide Transport
4
Cardiovascular System Development
8
Circulatory System Development
8
Hypermethylation (141 Genes)
Intrinsic Component of Plasma Membrane
23
Small Molecule Metabolic Process
20
Phosphate Containing Compound Metabolic Process
20
Cell Junction
15
Chemical Homeostasis
13
Response to Oxygen Containing Compound
16
Homeostatic Process
15
Tissue Development
16
Heart Development
9
Intracellular Signal Transduction
16
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p-value
5.79E-08
3.06E-07
1.91E-06
2.94E-06
2.95E-06
4.35E-06
8.02E-06
1.01E-05
1.22E-05
1.22E-05
3.50E-10
1.71E-07
9.90E-07
1.23E-06
1.57E-06
2.43E-06
7.51E-06
7.98E-06
8.86E-06
1.23E-05

Supp. Table 3.6 Gene Ontology of differentially methylated and differentially expressed
genes (iAs-rev v. iAsT). Gene ontology terms of both hypomethylated (180 genes) and
hypermethylated (241 genes) genes comparing iAs-rev to iAsT.
GO Term

Number of Genes
Hypomethylation (180 Genes)
Positive Regulation of Molecular Function
29
Intrinsic Component of Plasma Membrane
27
Intracellular Signal Transduction
26
Signal Transducer Activity
27
Cardiovascular System Development
18
Circulatory System Development
18
Signaling Receptor Activity
23
Cell Development
23
Receptor Activity
24
Positive Regulation of Response to Stimulus
26
Hypermethylation (241 Genes)
Intrinsic Component of Plasma Membrane
41
Negative Regulation of Cell Death
24
Regulation of Cell Death
30
Phosphate Containing Compound Metabolic Process
35
Intracellular Signal Transduction
31
Response to Oxygen Containing Compound
29
Tissue Development
30
Movement of Cell or Subcellular Component
27
Receptor Binding
29
Neurogenesis
28
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p-value
4.89E-12
2.28E-11
4.51E-11
6.76E-11
3.83E-10
3.83E-10
6.92E-10
1.08E-09
3.38E-09
3.41E-09
1.15E-17
1.35E-11
5.55E-11
5.61E-11
5.81E-11
5.95E-11
1.16E-10
2.40E-10
2.79E-10
4.04E-10

Supp. Table 3.7 Alternative splicing ANOVA for genes of interest. Alternative splicing
reads collected for all of the genes investigated for differential gene expression changes
performed in alternative splicing ANOVA.
Gene Symbol p-value(group) alt-splicing(group)
CORO1B
0.242728
0.867536
ARID5B
0.452318
0.985346
EPC1
0.535415
0.466164
PPME1
0.593614
0.0578084
PRDX1
0.825822
0.997596
DYNC1I2
0.882775
0.934455
CDH12
0.906168
0.409667
PPM1L
0.946555
0.338747
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Supp. Figure 3.1 Distribution of fold change of DNA methylation between groups.

(A). Distribution of all hypomethylated CpG sites for iAsT v. NT, iAs-rev v. NT, and iAsrev v. iAsT. (B). Distribution of all hypermethylated CpG sites for iAsT v. NT, iAs-rev v.
NT, and iAs-rev v. iAsT.
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Supp. Figure 3.2 Scatter plots of CpG methylation reads for hypermethylation and
hypomethylation within the three data sets.

(A). iAsT v. NT. (B). iAs-rev v. NT. (C). iAs-rev v. iAsT.
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Supp. Figure 3.3 Venn Diagrams describing overlaps between differentially methylated
genes in different treatment groups.

(A). Venn Diagram of differentially methylated genes for iAsT v. NT (8388 total genes)
and iAs-rev v. NT (5649 total genes). (B). Venn Diagram of differentially methylated
genes for iAsT v. NT (8388 total genes) and iAs-rev v. iAsT (10416 total genes). (C). Venn
Diagram of differentially methylated genes for iAs-rev v. NT (5649 total genes) and iAsrev v. iAsT (10416 total genes). Values within each circle identify the subset of methylated
genes that are unique to that set while the overlap indicates differentially methylated genes
found in both sets.
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Supp. Figure 3.4 Venn Diagrams describing DMRs that reversed in methylation status
after reversal of treatment.

(A). Venn Diagram depicting genes that were hypomethylated in iAsT cells (4236 total
genes) and were hypermethylated when comparing iAs-rev v. iAsT (7062 total genes). (B).
Venn Diagram describing genes that were hypermethylated in iAsT cells (5774 total
genes) and were hypomethylated when comparing iAs-rev to iAsT (5875 total genes).
Values within each circle identify the subset of methylated genes that are unique to that
set while the overlap indicates differentially methylated genes found in both sets.
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Supp. Figure 3.5 Venn Diagrams describing overlaps between differentially expressed
genes and differentially methylated genes.

(A). Venn Diagram of differentially expressed genes (829 total genes) and differentially
methylated genes in iAsT cells (8388 total genes). (B). Venn Diagram of differentially
expressed genes (829 total genes) and differentially methylated genes in iAs-rev cells
(5649 total genes). (C). Venn Diagram of differentially expressed genes (829 total genes)
and differentially methylated genes between iAs-rev and iAsT (10416 total genes). Values
within each circle identify the subset of methylated genes that are unique to that set while
the overlap indicates differentially methylated genes found in both sets.
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CHAPTER 4. THE EMERGING ROLE OF HISTONE H2B VARIANTS AS
ONCOHISTONES IN IAS-MEDIATED EPITHELIAL-TO-MESENCHYMAL
TRANSITION
Introduction
Millions of people around the world are chronically exposed to low levels of
inorganic arsenic (iAs) through drinking water, food, and occupation3,4,202,203. While
arsenic can be present in the environment in a variety of forms (organic or inorganic,
trivalent (3+) or pentavalent (5+)), the inorganic, trivalent state is the most toxic form
because it is most soluble in water and has a lone electron pair that can participate in bonds.
Inorganic arsenic can be released into the environment in a variety of ways. Specific
industries, such as mining and smelting, can release iAs into the ground water and air204,205.
Furthermore, certain agricultural processes, such as rice farming in China, can incorporate
iAs into crops if it is present in the soil or water being used to grow plants206,207. Exposure
to inorganic arsenic is a concern, not only globally, but also within the United States208-210.
There are many regions within the US where individuals are being exposed to iAs above
the EPA allowed limit of 10 µg/L (10 ppb)203. Exposure above the EPA limit can occur
when individuals work in a particular industry or consume crops that have inorganic
arsenic contaminants. However, the main mechanism of exposure in the US is through
untreated drinking water203. While the EPA regulates heavy metal contaminants in treated
drinking water, many people, especially in rural areas, consume drinking water from wells,
which are untreated sources.
An example of a region where this is a prevalent problem is Eastern Kentucky, where
the coal mining industry releases iAs into the ground water. In this region, many people
use well water as their main source; therefore, their water is not regulated by the EPA and
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contains low levels of iAs. Beyond that, many people live in this region for decades, so
they are being exposed to low doses of inorganic arsenic for a long period of time. In
Eastern Kentucky, cancer rates are higher than normal, specifically lung cancer rates211,212.
While there are many factors that contribute to the higher cancer rates seen in this area,
it’s probable that chronic, low dose exposure to inorganic arsenic could be one of those
contributing factors.
It has been shown, in lung cancer and in other cancer types, that chronic, low dose
iAs exposure promotes a specific process that progresses cancer development – the
epithelial-to-mesenchymal transition (EMT)63,124,213,214. EMT is the process by which
metastasis can occur in an individual. Through EMT, cells develop the ability to leave the
original tumor site, move to other regions in the body, and establish new tumors. Many
cells within our body are categorized as “epithelial” and exhibit cuboidal or spherical
morphology, adhesion to the surrounding cells and the basement membrane, and polarity
that allows them to function properly. Because of their adhesive properties, these cells are
stationary and are not able to travel throughout the body. When these cells go through the
epithelial-to-mesenchymal transition, they lose their polarity, lose their adhesive
properties, become elongated and spindle-like, and develop the ability to be mobile215,216.
This transition gives cells properties that are more indicative of a mesenchymal phenotype.
In our lab, and in other labs, this process is often studied in BEAS-2B cells, a normal
lung epithelial cell line. When BEAS-2B cells are treated with a chronic, low dose of
inorganic arsenic, they go through the epithelial-to-mesenchymal transition, making them
a good system to study this process. In order to study EMT as a process, our lab developed
a time course iAs treatment model in BEAS-2B cells to better understand the changes that
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occur throughout EMT. We begin with nontreated BEAS-2B cells (NT), which represent
the epithelial phenotype. Then, we treat BEAS-2B cells with a low dose of sodium arsenite
(0.5 µM) that is similar to levels that individuals would be exposed to in eastern Kentucky,
or other parts of the United States. Cells were grown with this low dose of iAs and were
harvested at three weeks (W3), eight weeks (W8), and seventeen weeks (W17).
Throughout a variety of experiments (wound healing assay, cell migration and invasion
assays, soft agar assay), our lab confirmed that these three time points reflect early EMT,
mid EMT, and late EMT, respectively. Then, to bring our cells to a fully transformed state,
we increased the dose of inorganic arsenic to 2.0 µM on the W17 cells until they had been
grown for 24 weeks (2.0T). By increasing the dose of iAs at this point, the cells began to
go through the reverse process – mesenchymal to epithelial transition (MET) – which is
characteristic of cells that are establishing a tumor in a new region during metastasis. Then,
we grew the 2.0T cells for another 3-6 weeks in the absence of iAs to identify what changes
may occur if iAs treatment is reversed. These cells are considered reverse-treated (RT) and
reflect a case in which someone may be exposed to inorganic arsenic over a long period
time, but then experience relief from that exposure.
While several mechanisms have been proposed to explain how iAs exposure
contributes to the epithelial-to-mesenchymal transition, one of the most prominent is the
role of epigenetic changes215,216. iAs is unique in that, unlike many other carcinogenic
agents, it does not cause DNA mutations217. iAs is not a mutagen. Instead, iAs is known
to cause epigenetic changes, which are changes to the DNA or proteins that compact it.
Epigenetic changes alter chromatin compaction and gene expression, but do not change
the DNA sequence. These epigenetic changes can occur either on the DNA itself, or on

93

the proteins which are responsible for compacting the DNA within the nucleus. At the
most basic level of chromatin compaction, DNA is wrapped about 1.7 times around a
histone octamer – a cylindrical structure containing two copies of each of the four core
histone types (H2A, H2B, H3, and H4). Epigenetic changes, such as DNA methylation
and histone post-translational modifications have been, and are being, well studied in
response to chronic, low dose iAs treatment30,218. However, a more unique epigenetic
change, incorporation of histone variants, has garnered less attention.
Cells produce canonical versions of each of the four main histone types that typically
get incorporated into most of the nucleosomes within the genome. However, cells also
produce variants of these histone proteins that can be incorporated into certain genomic
regions for specific purposes219. For example, histone variants, such as H2AZ.1, H2AZ.2,
and H3.3, get incorporated into regions where chromatin must be open so that gene
expression can be active220. Conversely, variants such as mH2A1 and mH2A2 get
incorporated into regions where chromatin needs to be compacted to prevent gene
expression91. Histone variants also serve specific purposes in the cell, such as promoting
developmental processes in early development or signaling regions of DNA damage to
recruit repair factors221-226.
Histone variants have been identified for histones H2A, H2B, and H3 and they can
differ from their canonical counterparts in several different ways219. Some histone variants,
such as mH2A and H2A.Z, have large regions of amino acid additions or deletions
compared to the canonical histone. Other histone variants, such as H3.3, have single amino
acid changes that make them distinct from the canonical histone. Histone variants with
large amino acid additions and deletions have been well studied because antibody-based
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techniques can be easily performed by exploiting the large changes in amino acid
sequence. Investigation of histone variants containing single amino acid changes, on the
other hand, has not been performed as readily because of the lack of antibodies with
sufficient specificity. Interestingly, histone variants with single amino acid changes are
beginning to gain more attention as mutations in histones are being identified and
implicated in a variety of disease states, especially cancer. In the past few years,
researchers have identified many mutations that occur in the canonical histone sequence
that can promote and contribute to cancer development227-229. These histone mutants,
termed “oncohistones,” get incorporated into the genome and alter chromatin compaction,
thereby altering gene expression patterns that promote carcinogenesis. While histone
variants are not mutants, the effect of a single amino acid change in a histone mutant begs
the question of whether histone variants with point amino acid changes could function as
oncohistones, as well.
This question is most relevant for histone H2B variants, which do not exhibit large
amino acid additions or deletions, but only exhibit a few single changes, spread throughout
the amino acid sequence (Figure 4.1A). There are sixteen variants of histone H2B and our
lab identified ten that are dysregulated, both at protein and mRNA levels, in response to
chronic, low dose exposure to iAs63. Some of these variants, such as H2BH and H2BN,
only have one amino acid variation in the tail region of the histone protein. Other variants,
such as H2BK or H2BE, only have one amino acid variation in the core region of the
histone protein. There are also several histone H2B variants, such as H2BJ or H2BB, that
have two or three amino acid variations spread throughout the sequence (Figure 4.1A).
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While the effect of many of the amino acid changes is not yet known, two of the
amino acid variations can be investigated using PyMol and structures available in the PDB
(Figure 4.1B). The amino acid variation that occurs at amino acid position 39 is located at
the interface between histone H2B and the DNA that is wrapped around the octamer. In
canonical H2B (H2BC), as well as several of the variants, this amino acid is a valine.
However, in four of the variants, this amino acid position is an isoleucine instead. In
looking at these amino acid residues within the structure, it appears that an isoleucine at
this position is able to project closer to the DNA, potentially causing a steric clash that
would prevent the DNA from wrapping as tightly around the histone octamer (Figure
4.1C). Furthermore, the amino acid variation that occurs at amino acid position 124 is at
the interface between histone H2B and histone H2A. In canonical H2B and most of the
variants, this amino acid is a serine. However, in H2B variants H2BJ and H2BK, this
amino acid position is an alanine instead. When investigating this amino acid, it’s apparent
that when serine is present, it forms a hydrogen bond with an adjacent arginine from H2A,
thereby forming a stabilizing connection between histone H2A and H2B (Figure 4.1D).
However, when this amino acid is an alanine instead, that hydrogen bond is lost, which
could alter the interaction between histones H2A and H2B within the histone octamer.
While structural data suggests the amino acid variations in histone H2B variants could
cause major changes in nucleosome stability and DNA compaction, no work has yet been
done to identify the specific impact of histone H2B variants on octamer and nucleosome
dynamics. Despite this gap in knowledge, dysregulation of histone H2B variants has been
identified in many cancer types and dysregulation of each of the variants seems to be
cancer and cell type specific.

96

Using data from cBioPortal, gene expression data for the histone H2B variants was
extracted for a variety of cancer types. It’s clear from the data that dysregulation of histone
H2B variant gene expression is cell type and cancer type specific. Dysregulation of histone
H2B gene expression seems to be most prevalent in breast, bladder, prostate, and uterine
cancers (Figure 4.2A). Some cancers exhibit mild upregulation or downregulation of the
histone H2B variant genes while others exhibit severe changes in gene expression of
several variants (Figure 4.2B). For example, prostate cancer shows significant
upregulation of HIST1H2BE, HIST1H2BC, HIST2H2BF, and HIST1H2BF. On the other
hand, low grade glioma (LGG) shows noticeable downregulation of HIST1H2BD,
HIST1H2BK, and HIST1H2BE. Interestingly, H2B variant genes seem to be particularly
upregulated in cancers involving reproductive organs such as testicular, cervical, ovarian,
uterine, and breast. For example, HIST1H2BC is upregulated in prostate and testicular
cancer while HIST1H2BJ is upregulated in cervical, ovarian, and testicular cancer. It has
been suggested that iAs drives cancers that involve Hedgehog signaling, such as pancreatic
and esophageal cancer. Interestingly, both pancreatic and esophageal cancer show
consistent downregulation of the histone H2B variant genes. Furthermore, inorganic
arsenic is known to promote squamous cell cancers which include lung squamous cell
carcinoma, head and neck, and cervical cancer230-234. However, differences in expression
of the histone H2B variant genes in these types of cancer are moderate.
The aim of my work has been to understand the role of histone H2B variants, not
only in the context of iAs-induced carcinogenesis, but also in the context of chromatin
compaction. Our preliminary data indicated that histone H2B variants are dysregulated in
response to iAs exposure63. I sought to identify how histone H2B variants are being
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dysregulated, and the unique role that they may be playing in the epithelial-tomesenchymal transition during chronic, low dose iAs treatment. Furthermore, I sought to
understand how these histone H2B variants could be influencing octamer stability,
nucleosome stability, and DNA accessibility when they are incorporated into the genome.
This work has progressed our understanding of histone H2B variants and lays a foundation
to discern their role not only in disease states, but also in normal cellular functioning.

Results
4.2.1 Dysregulation of Histone H2B Expression
As mentioned previously, earlier studies in the lab had identified that ten histone
H2B variants were dysregulated both at the gene expression (as measured by quantitative
real time PCR) and protein levels (as measured by mass spectrometry)63. Each variant
exhibited unique changes in iAs-induced dysregulation, with some being upregulated and
others downregulated. However, these initial studies were only performed on cells that had
been treated with iAs for eight weeks. Therefore, I wanted to evaluate how expression of
the histone H2B variants changes throughout time course treatment with iAs. Using
quantitative real time PCR (qRT-PCR), I first identified the expression pattern for
canonical histone H2BC (Figure 4.3). H2BC exhibited mild expression changes with an
initial rise in expression at W3 and then a small drop in expression at W8. Then, expression
steadily increases back toward a more normal level through W17 and 2.0T. Then,
expression drops slightly once again with reverse treatment. While these trends were
intriguing, the changes seen with the histone H2B variants were even more interesting.
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Expression of the histone H2B variants showed similar trends as H2BC, but the
dysregulation was much more pronounced (Figure 4.3). Expression increased at W3, but
much more so than the canonical H2B, and expression decreased at W8, but much more
so than the canonical H2B. Then, as treatment continued in W17 and 2.0T, expression of
some of the histone H2B variants did not recover back to normal levels, while others
overshot the normal level and increased drastically. Then, upon reverse treatment, the
expression of some of the H2B variants was maintained, while the expression of others
was further increased. These results indicated that the histone H2B variants are, in fact,
being dysregulated in response to chronic, low dose exposure to iAs. To continue my
investigation, I wanted to consider what could be causing these iAs-induced expression
changes.

4.2.2 Dysregulation of Stem Loop Binding Protein
In order to understand the underlying mechanism of these expression changes, it is
first essential to understand a unique property of histone mRNA. Most mRNA within the
cell contains a polyA tail at the 3’ end that is composed of 150-250 adenine nucleotides
and protects the mRNA from degradation, while also helping its translation efficiency.
This is helped by the binding of protein factors, such as the polyA binding protein, to the
polyA tail that facilitate mRNA processing and translation. Histone mRNAs are unlike
most mRNA within the cell because they do not contain a polyA tail at the 3’ end220.
Instead, histone mRNA has a 3’ stem loop structure, in which the single stranded mRNA
folds back and base pairs with itself to form a stem loop structure. Since polyA binding
protein is not able to bind to this 3’ structure to help the mRNA remain stable and get
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translated, there is a different protein responsible for that function for histone
mRNA70,76,220.
Stem loop binding protein (SLBP) is responsible for binding to the 3’ stem loop and
stabilizing histone mRNA. It prevents degradation of histone mRNA and promotes
translation. However, other studies have shown that in response to 24- or 48-hour exposure
to inorganic arsenic, SLBP levels are depleted70,76. Acute iAs exposure causes reduced
gene expression for SLBP and increased degradation by the proteasome. Therefore, SLBP
levels are reduced in response to iAs exposure. However, there have not yet been any
studies to identify how SLBP levels are dysregulated by chronic exposure to iAs. I used
qRT-PCR to identify changes in gene expression for the gene that encodes SLBP
throughout our chronic, low dose iAs treatment model (Figure 4.4A). Upon initial
treatment with iAs at W3, I saw what I expected – a significant reduction in SLBP mRNA
levels. However, the trend seen over time was surprising. During treatment through W8
and W17, it seems that SLBP expression is somehow able to adapt and recover back
towards normal expression levels. However, once the dose of iAs is increased to 2.0 µM,
SLBP expression is not able to maintain its recovery and drops back down to about 60%
of NT mRNA levels. Then, upon reversal of treatment, SLBP expression continues to drop
to about 25% of NT mRNA levels. I also performed Western Blot to confirm if SLBP
protein levels exhibit similar changes to gene expression. Although the antibodies
available on the market for SLBP are not 100% specific, Western Blot showed that protein
levels of SLBP follow a similar trend to mRNA level changes throughout chronic, iAs
treatment (Figure 4.4B).
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4.2.3 Dysregulation of Histone Transcript Polyadenylation
These results indicated that iAs-induced dysregulation of SLBP is more complicated
than what is seen in response to acute iAs treatment. SLBP levels undulate throughout
chronic, low dose exposure to inorganic arsenic. Because of the responsibility of SLBP to
bind and stabilize histone transcripts, it’s likely that the changes in SLBP levels contribute
to the changes in histone H2B expression. Interestingly, this story becomes even more
complicated when considering the relationship between SLBP and histone H2B variant
mRNA. Unlike canonical histone mRNA, which can only have a stem loop, histone variant
mRNA can have either a 3’ stem loop or a polyA tail. I hypothesize that at times when
SLBP is depleted, histone variant transcripts containing a polyA tail could be
compensating for the loss of canonical histone mRNAs.
In order to answer that question, I wanted to, once again, perform quantitative real
time PCR, but only on histone transcripts containing a polyA tail. I performed polyA
extraction to purify only those transcripts containing a polyA tail, and then analyzed
expression by qRT-PCR (Supplemental Figure 4.1). I found that each of the
polyadenylated histone H2B transcripts exhibited a similar trend in expression (Figure
4.5). Expression of the polyA transcripts drops slightly at W3, increased at W8, drops at
W17, and then goes back up at W24 and RT. This undulating expression pattern begins to
make a lot of sense when we combine it with the expression pattern seen for SLBP (Figure
4.6).
Upon initial treatment with iAs, SLBP levels drop. Therefore, there is less SLBP
available to stabilize histone transcripts and they are more likely to be degraded. To make
up for the loss of canonical histone transcripts, we see a subsequent rise in expression of
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polyadenylated histone H2B variant transcripts in W8. Then, as SLBP expression adapts
and recovers back to normal levels in W8 and W17, canonical, stem-looped H2B
transcripts are able to be stabilized and translated once again. Therefore, there is not a need
for compensation by polyadenylated H2B variant transcripts, so we see a subsequent drop
in expression of polyadenylated transcripts at W17. However, when SLBP levels drop
again upon the increase of the dose of iAs to 2.0 µM, an increase in expression of
polyadenylated histone H2B variant transcripts is seen again to compensate for the loss of
stem-looped H2B transcripts. In evaluating these trends, I also identified that not only does
a rise in expression of polyadenylated transcripts occur at W8 and 2.0T, but polyadenylated
transcripts also make up a great proportion of total transcripts for each of the histone H2B
variants (Figure 4.7).
Based on these trends, it seems that throughout chronic, low dose treatment with iAs,
SLBP is dysregulated both at the gene expression and protein level. Since SLBP is
responsible for stabilizing stem-looped histone transcripts, changes in SLBP levels
throughout iAs treatment cause changes in expression of the histone H2B variants.
However, histone H2B variants can have either a stem loop or a polyA tail at the 3’ end,
so polyadenylated histone H2B variants are not as impacted in stability by changes in
SLBP219,220. It seems that whenever SLBP levels are reduced, expression of
polyadenylated histone H2B variants rises to compensate for the loss of stem-looped
canonical histone transcripts.
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4.2.4 Dysregulation of Histone Transcript Stability
As suggested earlier, histone transcript stability is disrupted by iAs treatment because
SLBP, which is responsible for stabilizing histone transcripts with stem-loop structures, is
dysregulated in response to iAs treatment70,76. However, just like with SLBP levels, this
has only been studied in response to 24- or 48-hour treatment with inorganic arsenic. To
identify how histone transcript stability is altered throughout chronic, low dose exposure
to iAs, steady state levels of histone mRNA were evaluated using qRT-PCR after treating
cells with actinomycin D, an agent that halts transcription. By evaluating mRNA samples
at several time points post actinomycin D treatment, a half-life for each histone variant
transcript could be identified in each iAs treatment group.
The data indicate that, in general, histone variant transcripts are more resistant to
degradation than the canonical histone H2BC transcript (Figure 4.8). This is seen in the
longer half-lives exhibited by the histone variant transcripts (Table 4.1). However, this
trend is not clear-cut throughout each treatment group. At times throughout iAs treatment,
such as W3 and 2.0T, the H2BC transcript actually exhibits greater stability than the
variant transcripts. Therefore, it is likely that stability is of the histone H2BC transcript is
influenced by the undulating changes in SLBP levels. However, more investigation will
be needed to confirm these findings and further elucidate how chronic, low dose iAs
treatment alters histone transcript stability and turnover through changes in SLBP.

4.2.5 Dysregulation of Chromatin Compaction by Histone H2B Variants
If these histone H2B variants are being dysregulated in response to iAs exposure,
what effect are they having within the genome when they get incorporated into
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nucleosomes? In order to answer this question, I used three different techniques – salt
fractionation, thermal stability assay, and MNase digest. First, I used a salt fractionation
assay, in which chromatin is extracted from cells and then incubated in increasing
concentrations of salt buffer. Less compact chromatin is more susceptible to elution in the
low salt concentration, while more compact chromatin does not elute until it is perturbed
by a much higher salt concentration235. Using this assay, I have identified that chronic, low
dose exposure to iAs results in increased global chromatin compaction (Figure 4.9A).
Furthermore, the use of antibodies in development at ThermoFisher confirmed the
presence of some histone H2B variants in the most compact chromatin. Antibody 48430
identified the presence of histone variants H2BJ and H2BK, while antibody 48815
identified the presence of histone variant H2BB and H2BN (Figure 4.9B and C). It is
probable that the presence and dysregulation of histone H2B variants could be contributing
to the global chromatin compaction seen throughout iAs treatment.
Second, in order to investigate how histone H2B variants influence octamer and
nucleosome stability, I used a thermal stability assay. The melting temperature of an H2B
variant-containing octamer or nucleosome was measured at multiple salt concentrations,
thereby evaluating both temperature and salt stability. For these experiments, I focused on
evaluating four different histone H2B variants in addition to H2BC (canonical). Several
factors were considered in deciding to focus my studies on histone variants H2BB, H2BD,
H2BJ, and H2BK. First, our preliminary mass spectrometry data indicated that H2BJ and
H2BK were upregulated, while H2BB and H2BD were downregulated63. Furthermore,
each of these variants exhibit a different combination of the amino acid variations at
position 39 and position 124 that could be evaluated through PDB structures (Figure 4.1).
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Therefore, the effect of these histone H2B variants on octamer and nucleosome dynamics
could be associated to different amino acid variations or combinations of variations.
To begin, I performed the thermal stability assay on histone octamers containing
either canonical H2BC or one of the four histone H2B variants. These experiments were
performed at 0.5M, 1M, 1.5M, and 2M salt (Figure 4.10A-D). Dissociation of the histone
octamer and nucleosome are sensitive to changes in salt concentration, so I wanted to
ensure that changes in stability due to the histone H2B variants would be consistent at a
variety of different salt concentrations. The melting temperature measured for each
indicates the point at which the melting curve is the steepest as it arrives to its peak. The
peaks varies for each octamer or nucleosome based on the unique interactions with the
SYPRO Orange dye as melting occurs. I found that at each salt concentration tested, the
histone octamer containing histone H2BC melts at a lower temperature that the octamers
containing a histone H2B variants (Figure 4.11). This suggests that the canonical histone
octamer is actually less stable than the H2B variant-containing octamers.
I next performed similar thermal stability assays on nucleosomes containing the
different histone H2B variants (Figure 4.12A-D). Each nucleosome consisted of a histone
octamer wrapped by 147 base pairs of the 601 DNA sequence. Nucleosomes exhibit two
step melting because the H2A-H2B dimer dissociates first, followed by the H3-H4
tetramer dissociation236. Therefore, two different melting temperatures had to be
calculated. I found that for the first melting temperature, in which the H2A-H2B dimer is
dissociating, the trends in melting temperatures correlate to the amino acid variations
characteristic of each variant (Figure 4.13A). The nucleosome containing H2BD, which
does not have any variations at amino acid position 39 or 124, is actually more stable that
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the normal nucleosome, melting at a higher temperature at each salt concentration. The
nucleosomes containing H2BB, H2BJ, and H2BK are less stable than the normal
nucleosome, each melting at a lower salt concentration. As expected, the melting
temperatures for the dissociation of the H3-H4 tetramer did not differ because the H2B
variants have dissociated and denatured at this point (Figure 4.13B). From these results, it
seems that when DNA is wrapped around the histone octamer to form a nucleosome,
variations at amino acid positions 39 and 124 lead to a less stable nucleosome structure.
Finally, I performed an MNase digest experiment on nucleosomes containing 247
base pairs of DNA wrapped around a histone octamer containing one of the histone H2B
variants. In this experiment, I was able to determine if the accessibility of DNA to MNase
is influenced by the presence of a histone H2B variant. I found that DNA is less accessible
to MNase when one of the histone H2B variants is incorporated into the nucleosome
(Figure 4.14). DNA wrapped around the wild type histone octamer is much more sensitive
to MNase digestion than the DNA wrapped around H2B variant-containing histone
octamers.

Discussion
The work presented here showcases the potential role of histone H2B variants in
inorganic

arsenic-mediated

cancer

development.

Throughout

the

epithelial-to-

mesenchymal transition, not only does expression of histone H2B variants change, but the
RNA processing that occurs at the 3’ end of histone variant transcripts changes as well.
H2B variants with a polyA tail are present in a greater amount to compensate for the loss
of SLBP, and subsequent reduction in stabilization of canonical, stem-looped H2B
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transcripts. Since the polyadenylated histone H2B variant transcripts are more stable and
persist longer in the cell, it’s plausible that they could be incorporating into the chromatin
in inordinate amounts, thereby disrupting normal gene expression patterns70,76.
My biophysical experiments indicated that, in general, the incorporation of a histone
H2B variant into an octamer or nucleosome leads to a more stable structure (Figure 4.11
and 4.12). Not only do histone octamers exhibit greater stability when an H2B variant is
present, but the DNA is less accessible as well (Figure 4.14). It’s clear that histone H2B
variants influence octamer and nucleosome dynamics and could alter compaction,
accessibility, and chromatin compaction wherever they are incorporated.
My work is consistent with our previously published data that highlighted the novel
finding that histone H2B variants exhibit changes in response to low dose, iAs exposure
at both the mRNA and protein level63. This study expanded that previous investigation by
identifying changes to H2B expression over a longer period of time and at multiple time
points. Through this more expansive study, I was able to more intricately identify changes
in H2B variant expression throughout the process of the epithelial-to-mesenchymal
transition (Figure 4.3). It is evident that disruption of SLBP levels drives the pattern of
H2B variant expression seen throughout chronic treatment with iAs (Figure 4.4). My work
agrees with previously published data that indicates reduction of SLBP levels in response
to 24- or 48-hour exposure to inorganic arsenic70,76. However, treatment with iAs for a
longer period of time reveals more complex changes in SLBP expression and protein
levels.
The next logical step for this investigation would be to perform ChIP-Seq for the
histone H2B variants to determine the regions within the genome in which they are
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incorporated under normal conditions and iAs treatment conditions. Unfortunately, since
the histone H2B variants have only a few amino acid variations that are spread throughout
the protein, it has been difficult to develop antibodies that are specific to just one histone
H2B variant. In collaboration with ThermoFisher Scientific, we have contributed to
development of histone H2B variant antibodies; however, most of the antibodies exhibit
specificity to multiple histone H2B variants, preventing them from being useful for
Western Blot, much less ChIP-Seq experiments. In the current study, I was able to identify
changes to gene expression for each of the ten histone H2B variants, but I was not able to
correlate those gene expression changes to protein levels for each of the variants since
Western Blot could not be performed successfully. I hope that, eventually, effective
antibodies will be developed so that the sites of genomic incorporation for the histone H2B
variants can be identified. I conjecture that in response to iAs exposure, the histone H2B
variants are being incorporated into the genome more than they should and are causing
disruption in gene expression that is promoting carcinogenesis in our cells.
Until successful H2B variant antibodies are created, there are two available options
for delineating their incorporation into the genome. First, the currently available antibodies
could be used to perform ChIP-Seq. While these antibodies can’t distinguish between
individual histone variants, they can distinguish variants from canonical H2B. Therefore,
an experiment of this sort could provide insight on the genomic locations where histone
H2B variants, in general, are being incorporated. The other option is to create tagged
histone H2B variants and introduce them into cells. While this would allow for more
precise identification of genomic incorporation, it’s possible that these tagged histone H2B
variants may not be incorporated into the genome in the same locations that they would if
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they were being produced under normal conditions. I imagine that a combination of both
of these methods will be necessary to determine regions of genomic incorporation for the
histone H2B variants.
Beyond iAs-induced changes in expression, this work also indicated that the
incorporation of histone H2B variants into an octamer or nucleosome can disrupt normal
stability, compaction, and accessibility. This is consistent with the extensive data
characterizing the effect that histone H2A or H3 variants have on the nucleosome91,237,238.
However, this work is novel in that it is the first time that the histone H2B variants have
been investigated for their biophysical properties. While the structural effects of H2A and
H3 variants are more pronounced because of the large amino acid additions and deletions
present in those histone variants, our work suggests that the small point amino acid changes
found in the histone H2B variants can also influence nucleosome dynamics. This finding
is consistent with the current research being done on the role of mutant histones
(oncohistones) in cancer development227-229. A single amino acid mutation in a histone
protein can drive cancer progression; therefore, it is reasonable to believe that a single
amino acid change found in a histone variant could function similarly, if employed in the
wrong place at the wrong time.
This work provides unique insight for the emerging “oncohistone” field, which is
currently focused on histone mutations. While the histone H2B variants are not mutants,
they exhibit similar single amino acid changes compared to the canonical histone protein.
Therefore, histone mutants and histone variants could both be functioning similarly as
oncohistones. The work that is being done on histone mutants can and will inform the
investigatory path forward for understanding the role of histone H2B variants in disease
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states, such as iAs-induced cancer development. Conversely, the work done with histone
H2B variants and other histone variants will complement and reinforce the research being
done on histone mutants.
Because of the current lack of successful antibodies, histone H2B variants have been
the least studied histone variant. While much research has shown the influence of H2A
and H3 variants in normal functioning, as well as disease states, there is still a lot of work
that needs to be done to understand the function of histone H2B variants. Before we can
characterize the impact of histone H2B variants in a disease state, we first must understand
their role in normal cellular functioning. While the current study began investigating
histone H2B variants biophysically, further studies are needed to elucidate how histone
H2B variants influence DNA target site accessibility, nucleosome remodeling, and
nucleosome stability.
This study is the first not only to characterize histone H2B variants in a disease state,
but also to begin to understand their role in normal nucleosomal functioning. Histone H2B
variants create a more compact octamer and nucleosome structure and reduce DNA
accessibility. In response to chronic, low dose iAs exposure, H2B variants exhibit an
undulating expression pattern that is brought upon by an undulating pattern in SLBP levels.
Expression of polyadenylated histone H2B transcripts responds to changes in SLBP levels
in order to adapt and compensate for the reduced stability of canonical histone H2B
transcripts. The dysregulation of histone H2B variants by SLBP most likely alters gene
expression patterns that promote the epithelial-to-mesenchymal transition observed in
response to chronic, low dose iAs treatment.
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Table 4.1 Half-lives of histone H2B transcripts in response to actinomycin D treatment.

Treatment
Group
NT
W3
W8
W17
2.0T
RT
Treatment
Group
NT
W3
W8
W17
2.0T
RT

C

B

Histone H2B Transcript – Half Life
D
J
K

H

30.40
15.10
23.49
111.80
92.82
43.99
84.20
53.72
62.05
80.54
81.32
58.03
76.87
107.00
72.28
65.67
75.86
89.20
40.92
30.73
42.20
71.92
72.13
57.62
200.10
22863.00 93.54
71.18
99.05
66.59
104.10
99.67
132.10
170.10
215.20
105.50
Histone H2B Transcript – 95% Confidence Interval for Half Life
C
B
D
J
K
H
23.04 to
40.57
67.69 to
106.4
61.52 to
97.55
36.62 to
46.05
46.09 to
???
66.15 to
170.6

8.342 to
23.53
42.79 to
68.30
61.75 to
225.6
23.47 to
41.44
94.89 to
???
69.70 to
147.0

15.83 to
34.72
52.91 to
73.21
57.41 to
92.49
30.36 to
62.82
46.92 to
1780
80.25 to
242.5

53.85 to
327.0
75.16 to
86.42
55.52 to
78.30
57.93 to
90.17
50.50 to
117.8
99.88 to
341.0

63.70 to
142.8
68.99 to
96.76
69.61 to
82.89
63.32 to
82.45
49.45 to
2530
105.3 to
740.7

29.76 to
66.52
50.05 to
67.66
64.38 to
128.4
45.12 to
75.35
32.76 to
1119
72.91 to
158.0

Histone variant transcript stability was measured using qRT-PCR after actinomycin
treatment for multiple time points. Relative amounts of transcripts were graphed and halflife was measured (in minutes) for each transcript in each treatment group. Half-life was
measured using non-linear one-phase decay function.
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Figure 4.1 Histone H2B variants exhibit small amino acid changes - some of which are
present at histone:DNA or histone:histone interfaces.

(A). Diagram showing amino acid variations (boxed in black) in the ten histone H2B
variants identified in our study as being differential expressed in response to chronic,
inorganic arsenic treatment. (B). Nucleosome structure with amino acid variant positions
39 and 124 in histone H2B pointed out in red. (C). Amino acid variation at position 39 on
histone H2B with canonical valine in green and variant isoleucine overlayed in turquoise.
(D). Amino acid variation at position 124 on histone H2B with canonical serine in green
and variant alanine overlayed in turquoise.
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Figure 4.2 Dysregulation of H2B variant expression is cancer and cell type specific.

(A). Bar graph depicting incidences of histone H2B mutations in different cancer types, as
identified by cBioPortal. (B). Heat map depicting expression changes of histone H2B
variant genes in a variety of cancer types, as identified by the Cancer Genome Atlas.
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Figure 4.3 Chronic, low dose exposure to iAs disrupts expression of histone H2B variant
transcripts.
2.2
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The ten histone H2B genes, measured by qRT-PCR, exhibited changes in total expression
over the course of chronic, low dose iAs exposure. Most variants shared a similar pattern
with increased expression upon initial treatment and a large drop in expression after eight
weeks of treatment. Then, expression levels rose back towards the nontreated level with
further treatment.
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Figure 4.4 iAs exposure disrupts expression of stem loop binding protein (SLBP).

(A). Gene expression changes of gene encoding SLBP throughout chronic, low dose
exposure to inorganic arsenic, as measured by quantitative real time PCR. (B). Western
Blot depicting changes in protein level of SLBP throughout iAs treatment. Central band is
SLBP. Top band is phosphorylated SLBP and bottom band is non-specific binding. TBP
was used as control.
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Figure 4.5 Expression of polyadenylated histone H2B variant transcripts follow an
undulating pattern throughout iAs treatment.
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Histone H2B mRNA transcripts containing a polyA tail were measured using quantitative
real time PCR. Polyadenylated transcripts increase in expression at W8, 2.0T and RT.
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Figure 4.6 Expression of histone H2B variant polyA expression correlates to changes in
SLBP expression.

1.2
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This graph depicts expression of SLBP and general expression trend of the polyadenylated
histone H2B variants, as determined by quantitative real time PCR. Increases in expression
of polyadenylated histone H2B variants follows drops in SLBP expression, while
decreases in expression of polyadenylated histone H2B variants follows increases in SLBP
expression.
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Figure 4.7 PolyA transcripts comprise a greater ratio of total H2B variant expression
during iAs exposure.
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Graph depicting ratio of relative expression of polyadenylated transcripts to total
transcripts for histone H2B variants. Polyadenylated transcripts comprise a greater ratio of
total expression for each variant at week 8 and 2.0T.
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Figure 4.8 Histone H2B variant transcripts exhibit differential stability throughout
chronic, low dose iAs treatment.

Transcript levels for histone H2B C, B, D, J, K, and H were measure via qRT-PCR at
multiple points for each of the six treatment groups. qRT-PCR data presented as mean ±
SEM of half-life through 3 technical replicates. Data was fit to a non-linear one-phase
decay function to determine half-life. Variants display various patterns of stability
throughout iAs treatment.
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Figure 4.9 iAs treatment causes global chromatin compaction.

(A). Salt fractionation was used to determine compaction of chromatin throughout iAs
treatment. Chromatin compaction increases as iAs treatment progresses. (B). Western Blot
of resuspended precipitates for each salt fraction with trial antibody from Thermo Fisher
that binds to H2B variants J and K. (C). Western Blot of salt fractions with trial antibody
from Thermo Fisher that binds to H2B variant B.
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Figure 4.10 Histone H2B variant-containing octamers exhibit differential stability at a
variety of salt concentrations.

(A). Thermal stability assay of histone H2B variant-containing octamers at 0.5M NaCl.
(B). Thermal stability assay of histone H2B variant-containing octamers at 1M NaCl.
(C). Thermal stability assay of histone H2B variant-containing octamers at 1.5M NaCl.
(D). Thermal stability assay of histone H2B variant-containing octamers at 2M NaCl
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Figure 4.11 Wildtype histone octamer is less stable than H2B variant-containing histone
octamers.
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Wildtype histone octamer melts at a lower temperature than all of the H2B-variant
containing octamers at each salt concentration. WT melting temperature is significantly
different than variant melting temperatures at 0.5, 1.0, and 1.5M salt concentrations.
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Figure 4.12 Histone H2B variant-containing nucleosomes exhibit two-step melting and
differential stability at a variety of salt concentrations.

(A). Thermal stability assay of histone H2B variant-containing nucleosomes at 0.5M NaCl.
(B). Thermal stability assay of histone H2B variant-containing nucleosomes at 1M NaCl.
(C). Thermal stability assay of histone H2B variant-containing nucleosomes at 1.5M NaCl.
(D). Thermal stability assay of histone H2B variant-containing nucleosomes at 2M NaCl
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Figure 4.13 Histone H2B variant-containing nucleosomes exhibit variation in stability
that corresponds to the amino acid changes found in each variant.

Nucleosomes exhibit two stage melting with the first stage (A) being the release of the
H2A-H2B dimers and the second stage (B) being the release of the H3-H4 tetramer236.
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Figure 4.14 Histone H2B variant-containing nucleosomes exhibit different DNA
accessibility to MNase digestion.

(A). MNase digestion of 247 bp 601 DNA wrapped around histone octamer containing
one of the histone H2B variants. Top row of bands is reconstituted nucleosome and lower
bands are subnucleosomal particles created by digestion239. (B). Graph of loss of
reconstituted nucleosome as measured by top row of bands for each time point using
function y=m1*(exp(-m2*m0).
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Supp. Figure 4.1 Transcripts containing polyA tail are successfully purified from nonpolyadenylated transcripts by polyA extraction.

Quantitative real time PCR was used to verify purification of polyA transcripts using
Promega PolyATtract® mRNA Isolation System. RPPH1 is transcript that does not
contain polyA tail.
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CHAPTER 5. CONCLUSIONS
iAs Promotes the Epithelial to Mesenchymal Transition
Throughout the world and in the United States, numerous individuals are exposed to
low levels of inorganic arsenic through drinking water, occupation, or contaminated food
sources1,4,217. While exposure, oftentimes, does not occur above 1 µM, chronic exposure
to low levels of iAs can contribute to the development of several disease states156,157,240,241.
Numerous studies have linked iAs exposure to cardiovascular disease, diabetes, and
cancer156,157,240. Regions in which iAs exposure is common exhibit higher incidences in
many cancer types, including lung, prostate, and bladder cancer157,241-244. It has been shown
that iAs contributes to cancer development by promoting a specific carcinogenic process
– the epithelial-to-mesenchymal transition25,124,214,245. This process is responsible for
metastasis, in which tumor cells can leave their site of origin and establish new tumors in
other locations throughout the body215,216,246. During EMT, cells change in morphology
and lose their adhesive properties so that they can become mobile. Then, once cells begin
forming a new tumor in another location, they revert back to an epithelial phenotype,
through the process of MET.
Several mechanisms have been identified for how iAs progresses EMT and cancer
development. For example, chronic, low dose iAs exposure is known to increase oxidative
stress, reduce DNA repair, and lead to large chromosomal aberrations13,247-249.
Interestingly, iAs is not mutagenic. Instead, iAs causes a variety of changes to the
epigenome, which alter chromatin compaction and gene expression patterns to promote
carcinogenesis39,214,250. While iAs has been shown to influence epigenetic regulators such
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as histone PTMs, alternative splicing, and microRNAs, this study focused on the influence
of iAs on DNA methylation and histone variants.

iAs Disrupts DNA Methylation Patterns
Numerous studies have shown changes in global DNA methylation in response to
iAs25,31,39,213,218. However, our understanding of these changes has been limited because
the analysis was low resolution and methylation patterns varied by cell type and cancer
type. It is essential to use high resolution studies to identify changes in DNA methylation
patterns at specific genes and gene regions to more clearly elucidate how iAs modulates
this epigenetic mark to promote carcinogenesis. While hypermethylation may be observed
in some regions of the genome in response to iAs, hypomethylation may be observed in
other regions. Furthermore, methylation can cause either repression or activation of gene
expression based on the region where it is found. Therefore, high resolution studies are
more effective at identifying the unique iAs-mediated DNA methylation changes that are
occurring throughout the genome and how they are intricately altering gene expression
patterns to promote carcinogenesis.
My investigation in HeLa cells revealed that over 30,000 CpG sites are differentially
methylated in response to iAs exposure, with some being hypomethylated and others
hypermethylated. This differential methylation is concentrated at CpG islands, upstream
promoter regions, and gene bodies, which suggests functional implications for these iAsinduced changes. Particularly, gene ontology analysis revealed that methylation changes
occur at many genes involved with cell signaling, development, and metabolism.
Furthermore, this study revealed that some DNA methylation changes are transient and
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revert back to normal after iAs is removed, while others are more permanent and persist
even when the iAs is no longer present. This correlates to the moderate reversal of EMT
observed in cells that undergo reversal of iAs treatment and suggests that methylation
patterns may promote gene expression patterns that drive EMT.
My data revealed that many of the DNA methylation changes identified by
microarray analysis correlated to changes in gene expression. However, due to the vast
presence of hyper- and hypo-methylation, it’s plausible that not all CpG sites are
responsible for regulating transcription. Methylation at CpG may lead to other changes,
such as alterations in the presence of nearby epigenetic marks or the binding of regulatory
factors. More work will be needed to determine the various effects of hyper- and hypomethylation at specific genic regions in response to iAs. While profiling studies such as
these provide a large amount of information, it is imperative that future studies are done
to complement existing data and provide a more detailed analysis of the functional
consequences of the methylation changes.
As work continues in the field, it will be exciting to discover how DNA methylation
influences and interacts with other epigenetic marks, such as histone post-translational
modifications (PTMs). DNA methylation is already known to be coregulated with
H3K27me3, but I imagine that there is crosstalk with many other histone PTMs, as
well200,201. Histone PTMs can permit, increase, or restrict access to chromatin by
transcription factors and other regulators. It is probable that DNA methylation can and
does work in concert with histone PTMs to influence chromatin compaction and DNA
accessibility. Crosstalk between different epigenetic factors could be determined using
chromatin immunoprecipitation, by which the presence of multiple epigenetic factors can
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be identified in a specific genomic location. Furthermore, biophysical techniques could be
used to measure the combinatorial effects of multiple epigenetic marks present in a single
nucleosome. I expect that both of these strategies will be necessary to expand our
understanding of epigenetic crosstalk. Beyond that, more investigation is necessary to
determine how the “writers, readers, and erasers” of DNA methylation are connected to
and influenced by the DNA methylation changes identified in this study. Our lab has
identified that iAs-induced disruption of CTCF and DNMTs underlies many of the DNA
methylation changes observed in response to iAs exposure213,251. While this hints at a
particular mechanism, no one has yet determined how these DNA methylation changes
alter the binding of regulatory factors or transcription factors to hyper- or hypo-methylated
genomic regions.

iAs Alters Histone H2B Variant Levels
iAs is known to cause changes in expression, protein levels, and nucleosome
incorporation of several histone variants including H3.3, H2A.Z, and H2A.X70,76,252-254.
When these histone variants get integrated in the wrong locations at the wrong time, they
can disrupt normal gene expression patterns and contribute to iAs-induced
carcinogenesis63,227. Unfortunately, there is a large gap in the field regarding the role of
histone H2B variants in iAs-induced carcinogenesis. My studies revealed that histone H2B
variant transcripts are dysregulated at the transcript level in response to chronic, low dose
iAs exposure. This is due, in part, to disruption of SLBP levels which occurs because iAs
causes reduced expression and increased degradation of SLBP70,76. In response to chronic
iAs exposure, SLBP levels undulate and the expression of histone H2B variants responds.
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Whenever SLBP levels are reduced, expression of polyadenylated histone H2B transcripts
is increased to compensate for the loss of stability for stem looped histone H2B transcripts.
Upregulation of the histone H2B variants seems to contribute to a more compact chromatin
state, which is seen throughout chronic iAs treatment. My studies revealed that
incorporating histone H2B variants into a histone octamer or nucleosome alters
nucleosomal properties, such as stability and DNA accessibility. Since little work has been
done to investigate histone H2B variants, more investigation is necessary to elucidate their
role not only in iAs treatment conditions, but also in normal cellular functioning. Our lab
will continue to study histone H2B variants in the coming years, as outlined in the
following “Future Directions” section.

Future Directions
As this study continues in the Fondufe-Mittendorf lab, there are multiple avenues for
further investigation. Due to the lack of antibodies for the histone H2B variants, the focus
has shifted from in vitro assays to biophysical assays. While the thermal stability assays
and MNase digestion highlighted in my work provide details about the influence of histone
H2B variants on nucleosome structure, nucleosomes are dynamic entities and there are
multiple facets of their functioning that must be studied239.
In order to study the biophysical properties of histone H2B variant-containing
nucleosomes, the lab has been developing the capability to perform Fluorescence
Resonance Energy Transfer (FRET). FRET relies on the detection of distance between two
fluorophores based on the transfer of fluorescent energy from one fluorophore to another.
The emission spectra of the donor fluorophore (Cy3) overlaps with the excitation spectra
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of the acceptor fluorophore (Cy5) (Figure 5.1A). Therefore, when Cy3 is excited, it will
release an emission that will excite Cy5. When Cy5 gets excited by Cy3, its emission is
proportional to the distance between the two fluorophores. FRET is able to measure the
distance between two labeled entities by measuring differences in fluorescence between
the two fluorophores.
For the purpose of our experiments, a Cy3 end-labeled 601 DNA strand is wrapped
around a Cy5 labeled histone octamer containing one of the histone H2B variants (Figure
5.1B). FRET can be used to measure compaction of DNA around the histone octamer and
the amount of DNA unwrapping and breathing that is occurring255-257. FRET should be a
successful tool to measure changes in DNA breathing because, in our system, Cy3 and
Cy5 will be 2-6 nm apart which is within the 6 nm optimal distance for those fluorophores.
I anticipate that the FRET studies will show similar changes in nucleosome dynamics as
the thermal stability assay. However, FRET can be used to elucidate changes in
nucleosome dynamics beyond just breathing.
Our FRET system can be modified so that we can also use this technique to measure
DNA target site accessibility. In this case, a 601 DNA sequence with an engineered LexA
binding site will be wrapped around a histone octamer containing one of the four histone
H2B variants (Figure 5.1C)255,256. LexA, a DNA binding protein, will be titrated in to bind
to its target site. When LexA binds to its binding site on the DNA, it will destabilize the
interaction between the DNA and histone octamer, opening up the nucleosome and
decreasing FRET efficiency. The effectiveness of the LexA binding and its ability to
disrupt the FRET efficiency will indicate how accessible the DNA target is with different
histone H2B variants incorporated into the nucleosome. I hypothesize that the
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incorporation of these histone variants into the nucleosome system will have an impact on
the FRET efficiency and target site accessibility. For example, variants B and J, which
have the V39I amino acid change, are predicted to facilitate greater DNA accessibility
because of the way the isoleucine probes the DNA away from the histone. This experiment
will define the functional role of each histone H2B variant with regards to DNA target site
accessibility.
Beyond FRET experiments, this study can also be expanded with the use of
experiments utilizing radiolabeled DNA, similar to the MNase digest experiments shown
in Chapter 4239. One such experiment would involve digesting DNA with DNAse I instead
of MNase. This would allow for a more extensive identification of regions of DNA that
are more or less accessible to digestion when wrapped around octamers containing
different H2B variants (Figure 5.2A). For example, could histone H2B variants promote
more DNA accessibility at the nucleosome dyad versus the entry/exit regions? By titrating
DNase I into nucleosome assemblies and running DNA digestion products on a sequencing
gel, DNase I digestion patterns can be elucidated in the context of histone H2B variant
incorporation.
Similarly, radiolabeled DNA containing an engineered enzyme restriction site can be
wrapped around H2B variant-containing octamers to determine target site accessibility
(Figure 5.2B)239. By placing the restriction sites at different locations within the DNA
sequence, accessibility of different portions of the DNA can be determined in the presence
of histone H2B variants. Furthermore, this technique can also be used to evaluate
nucleosome sliding and remodeling. A remodeler, such as RSC or Nap1, can be introduced
so that the enzyme restriction site is buried within the nucleosome if remodeling or sliding
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occurs. Digestion patterns will then reveal the extent of nucleosome sliding and
remodeling when histone H2B variants are incorporated into the nucleosome.
Although antibody-based techniques are not yet possible for studying histone H2B
variants, the continuation of this project may explore the use of tagged histones. We are
currently collaborating with the lab of Dr. Jonathan Licht (University of Florida) to
develop HA-tagged histone H2B variants that we can introduce into our BEAS-2B cells258.
By introducing these tagged histone H2B variants into our cellular model, we may be able
to gain insight on the specific regions within the genome where these histone H2B variants
are being incorporated, both under normal conditions and in response to chronic, low dose
inorganic arsenic exposure. Furthermore, by overexpressing one or more of the histone
H2B variants, we may be able to identify specific cellular changes that are instigated by
these histone variants. It’s plausible that overexpression of the histone H2B variants could
promote EMT, since several of them are upregulated in iAs-mediated carcinogenesis and
a variety of other disease states.
In combination, these studies will move the field forward in understanding the effect
of histone H2B variants on nucleosome dynamics and iAs-induced carcinogenesis.
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Figure 5.1 Fluorescence Resonance Energy Transfer (FRET) can be used to further
investigate nucleosome dynamics.

(A). Schematic of FRET system. Green dot is donor fluorophore label (Cy3) and red dot
is acceptor fluorophore label (Cy5). (B). Schematic of FRET system for determining DNA
wrapping/unwrapping. (C). Schematic of FRET system for determining DNA target site
accessibility.
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Figure 5.2 Radiolabeled DNA can be used to study the influence of histone H2B variants
on nucleosome dynamics.

(A). Schematic of nucleosome design for DNase digest experiments to investigate the
influence of histone H2B variants on DNA accessibility. (B). Schematic of nucleosome
design to investigate the influence of histone H2B variant on nucleosome sliding and
remodeling.
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